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Background: The age-adjusted Helicobacter pylori (H. pylori) seroprevalence rate in
the adult population decreased from 51% to 34% from 1973 to 1994 in Vammala,
Finland, before the current use of antimicrobials in the treatment of helicobacter
gastritis. Almost all H. pylori infected individuals show elevated levels of specific
immunoglobin G (IgG) antibodies, but in about two-thirds of subjects the specific IgA
antibodies were elevated. Presence of H. pylori IgA antibodies has been associated
with a CagA-positive infection, which in turn is associated with an increased risk of
severe complications of H. pylori infection.
Aims: To accelerate the decline of H. pylori infection, and to examine risk factors for
H. pylori infection in Finnish young adults, we started a unique population-based,
voluntary ’screen-and-treat’ programme in primary health care practice, first as a pilot
study in 1994 and since 1996 extending the programme to include over 6000 young
adults  in  Vammala,  Finland.  We  aimed  to  determine  the  accuracy  of H. pylori IgG
and IgA antibody tests for adults in different age-groups, with special emphasis on the
presence of atrophic gastritis. The same enzyme immunoassay (EIA) tests were used
in the ‘screen-and-treat’ programme. We also studied whether an increase in the
number of IgA antibody-positive H. pylori patients  with  respect  to  age  is  a  cohort
phenomenon only, and how the elevated IgA antibody levels changed during
infection, and determined whether the proportion of subjects infected with CagA+ or
CagA- H. pylori strains has changed as the overall prevalence of H. pylori has
declined.
Participants and methods: A total of  3326 individuals aged 15-40 in 1996, and 716
subjects aged 15 and 584 aged 45 in 1997-2000 were screened for H. pylori infection
using serology. Altogether 4626 (75.7%) inhabitants participated in screening. Serum
IgG  and  IgA  antibodies  to H. pylori were determined and all antibody-positive
subjects were offered eradication therapy. The first-line treatment included:
amoxicillin 1g  b. i. d., metronidazole 400mg t. i. d., and lanzoprazole 30mg b. i. d.
for seven days. Retreatment for those whose first treatment failed, included
amoxicillin 1g, clarithromycin 500mg and lanzoprazole 30mg b. i. d. for seven days.
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The cure was verified by serology and occasionally by the 13C-Urea breath test
(UBT). A total of 561 consecutive adult patients were gastroscopied for clinical
indications. Biopsy samples were taken for histology and culture, and serum samples
were tested for H. pylori IgG and IgA antibodies and pepsinogen I (PGI) levels.
Results were considered helicobacter positive if culture or histology were positive.
Paired serum samples collected from 224 subjects in both 1973 and 1994 and paired
serum samples from 336 persons collected in both 1978-1980 and 1997-1998, stored
at -20C°, were reanalysed for H. pylori IgA antibodies using in-house assays for the
224 subjects and Pyloriset EIAs for the 336 persons. Serum samples collected from
408 subjects in 1973, from 503 subjects in 1994, and paired serum samples from 221
subjects collected both in 1973 and 1994, stored at -20C°, were reanalysed for CagA
antibodies using a recombinant CagA fragment by EIA.
Results: H. pylori seroprevalence  rates  were  39%  in  the  pilot  study,  12%  among
subjects aged 15-40 years in 1996, and 3% and 27% among the 15 and 45-year-old
subjects in 1997-2000, respectively. In the ‘screen-and-treat’ programme, the
eradication rates were 89.8% in the pilot study, 82.2% and 77.6% per-protocol and
71.9% and 62.9% in intention-to-treat in subjects invited in 1996 and 1997-2000,
respectively. H. pylori seroprevalence rates were calculated to have decreased to 19%
in the pilot study, to 4% among subjects aged 15-40 years, and to 2% and 12% among
the 15 and 45-year-old subjects, respectively. In multivariate analysis, crowding
variables in the childhood household, low education of the mother, current smoking
and alcohol consumption, unfavourable housing conditions, and sick leave due to
dyspepsia were independent risk factors for H. pylori infection. The H. pylori
antibody test for IgG was highly accurate in subjects aged 15-49, but the specificity
declined in older age-groups, in which the prevalence of atrophic gastritis increased.
The  sensitivity  of  the  IgA  test  increased  and  the  specificity  decreased  by  age.  The
exclusion of ‘false’ positive results for patients with atrophic gastritis clearly
improved the specificities of both the tests for older age-groups. The number of IgA-
positive subjects increased during the follow-up and there was an increase in elevated
IgA antibody levels, as well. The proportion of subjects infected with CagA+ H. pylori
strains had declined more rapidly than the proportion of subjects infected with CagA-
H. pylori strains in subjects aged 14-44.
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Conclusions: The primary health care system of Finland provided good possibilities
to organize this large-scale programme. It remains to be seen, how much this
intervention will reduce the burden of H. pylori associated diseases and related health
costs in this low prevalence area. Serologic assays based on IgG antibodies were
highly accurate in young age-groups and also among the elderly when those with
atrophic gastritis were excluded. The increase in the number of IgA antibody-positive
H. pylori patients with age was due not only to the birth cohort phenomenon and
seroconverters, but also to increasing IgA antibody levels during infection. It remains
to be seen in the future what are the clinical consequences of the rapid decline in
CagA+ H. pylori infection in subjects aged 14-44 years.
10
INTRODUCTION
Helicobacter pylori infection is a chronic infection which is mainly acquired in
childhood (Kosunen et al., 1997). The prevalence rates of H. pylori antibodies
increase with age in all populations (Mégraud, 1993). This has been explained by a
so-called cohort phenomenon: the persistence of childhood infections, which have
gradually decreased since the early 1900s (Banatvala et al., 1993a; Sipponen et al.,
1996). Low socioeconomic status, crowded living conditions and a lack of hot tap
water are risk factors for acquisition of the infection in early childhood (Malaty,
2007). H. pylori infection is chronic and does not usually heal without specific
eradication treatment. Almost all H. pylori infected subjects have elevated levels of
specific IgG antibodies, but only in about two thirds of them does the IgA titer exceed
the cut-off level (Kosunen et al., 1992).  An IgA antibody response during H. pylori
infection has been associated with peptic ulcer disease and gastric cancer (Aromaa et
al., 1996; Kosunen et al., 2005). In addition, the production of IgA antibodies is found
to be associated with a CagA positive infection (Rautelin et al., 2000) which in turn is
associated with an increased risk of severe complications of the infection, like peptic
ulcer disease, atrophic gastritis and intestinal metaplasia, and gastric cancer (Cover at
al., 1995;  Kuipers et al., 1995; Parsonnet et al., 1997).
Recommendations for the diagnostic methods used for detecting H. pylori infection
have changed and now it is even generally accepted that the role of serology in
detecting the infection is crucial. The latest European guidelines on the management
of H. pylori infection, the Maastricht III Consensus Report, emphasized the special
role of serology compared to other diagnostic tests (Malfertheiner et al., 2007). Proton
pump inhibitor (PPI) treatment prior to testing can lead to false negative results in
other diagnostic tests than serological assays. Serological tests are recommended to
diagnose H. pylori infection also in patients suffering from bleeding ulcers and
conditions with a low bacterial density (gastric atrophy, mucosa-associated lymphoid
tissue (MALT) lymphoma); both invasive and other non-invasive tests have
demonstrated a limited sensitivity in those patients. Quantitative serological assays
are reliable to be used also in the follow-up after eradication treatment. The limitation
of this method is that it may demonstrate a lower performance if the population has
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been actively treated for H. pylori infection, since after successful H. pylori
eradication therapy the antibodies decline slowly to normal levels (Veijola et al.,
2007).
The indications for eradication treatment have widened. According to the latest
European guidelines, strongly recommended indications for eradication therapy are
peptic ulcer disease, bleeding peptic ulcer, low-grade gastric MALT lymphoma,
atrophic gastritis, post-gastric cancer resection, gastric cancer in close relatives, and
patient’s wishes. Indications for treatment are also long-term maintenance treatment
with PPIs, start of using nonsteroidal anti-inflammatory drugs (NSAIDs), unexplained
iron deficiency anaemia and idiopathic thrombosytopenic purpura, according to the
latest guidelines. H. pylori ‘test and treat’ was regarded appropriate for patients with
uninvestigated dyspepsia (Malfertheiner et al., 2007).
Although it has been suggested that H. pylori eradication for gastric cancer prevention
in populations at risk should be evaluated (Malfertheiner et al., 2007), screening and
treating the general population for H. pylori has not yet been recommended. Although
the prevalence of H. pylori infection is steadily declining in developed countries, also
in Finland (Rehnberg-Laiho et al., 2001; Malaty, 2007), and the prevalence of H.
pylori associated peptic ulcer disease has declined (Veijola et al., 2005a; Koivisto et
al.,  2005),  the  severe  complications  of  the  infection  still  exist.  If  a  screening  and
treating for H. pylori programme could be offered to young adults in the general
population, it would be possible to cure the infection before the development of pre-
neoplastic conditions and also the transmission of the infection from parents to
children could be prevented.
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REVIEW OF THE LITERATURE
HISTORY OF H. PYLORI
The bacterium H. pylori has  been  present  for  at  least  3000  years.  The  presence  of
gastric spiral bacteria was first documented in 1893 by an Italian pathologist
Bizzozero, who found these bacteria in the stomach of dogs (Bucley et al., 1998).  In
the human stomach the bacteria were demonstrated in 1906 (Bucley et al., 1998).
Pathologist Robin Warren noticed helicobacters in 1979 during routine diagnostic
procedures, and in 1981 after having met Barry Marshall the modern story of H.
pylori and  peptic  ulcer  disease  began  (Marshall  and  Warren,  1983;  Bucley  et  al.
1998). Warren and Marshall found the association between Campylobacter like
organisms and gastritis and peptic ulceration and succeeded even to cultivate this
slow-growing organism. They also started the modern eradication of H. pylori with
antimicrobial agents, and were the first to suggest the possibility of the association of
H. pylori with gastric cancer (Marshall and Warren, 1983; Marshall and Warren,
1984). A causative association between H. pylori and  gastritis  was  proven  when
Marshall and Morris independently ingested the bacterium and observed the results
fulfilling the prerequisites of Koch’s postulates (Marshall et al., 1985; Morris and
Nicholson,  1987).  Warren  and  Marshall  were  awarded  with  the  Nobel  Prize  in
Medicine in 2005 emphasizing the importance of their observations on H. pylori and
peptic ulcer disease.
BACTERIOLOGY OF H. PYLORI
1. Bacteriology
H. pylori is a gram-negative, spiral-shaped, multi-flagellated bacterium that infects
the human gastric mucosa. It is microaerophilic and relatively slowly growing in
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culture, where it usually occurs in the form of straight or slightly curved rods
(Goodwin et al., 1985). Coccoidal forms of the bacterium may be seen after prolonged
culture (Mégraud et al., 1985). H. pylori is identified in culture by colony appearance,
Gram staining, and positive reactions for oxidase, urease, and catalase.
H. pylori has unique ability to survive in the acid environment of stomach due to the
bacterium’s ability to produce urease enzyme which splits urea to ammonium, and
due to an acid-regulated urea transport channel (Weeks et al., 2000). The bacterium
can also escape the gastric acidity with the aid of flagellae and penetrate into the
gastric mucus (Owen, 1998).
The genus Helicobacter comprises  of  31  formally  named  different  species  (List  of
Prokaryotic Names with Standing in Nomenclature (http://www.bacterio.cict.cict.fr
accessed 26th April 2008).
2. CagA and other virulence factors
Initial H. pylori colonization occurring mostly in childhood proceeds to chronic
persistent infection and inflammation, and in some of the infected individuals to
peptic ulcer disease, premalignant conditions and rarely to gastric cancer. The
progression of the infection depends on strain virulence, host genetic susceptibility
and environmental factors.
H. pylori strains  are  either  CagA-positive  or  CagA-negative  based  on  whether  they
produce a highly immunogenic128 kDa protein, which is encoded by the cagA gene.
Cytotoxin-associated gene cagA is a marker of the pathogenicity island (PAI), which
encodes disease-associated virulence factors of H. pylori (Censini et al., 1996;
Akopyants et al., 1998). CagA is present in 40 to 70% of H. pylori strains, and in the
Western world it is associated with peptic ulcers, precancerous conditions like
atrophic gastritis and gastric cancer according to several studies (Cover at al., 1995;
Kuipers et al., 1995; Parsonnet at al., 1997; Kusters et al., 2006).  CagA-positive
strains have also been reported to associate with non-ulcer dyspepsia (Ching et al.,
1996; Loffeld et al., 2001). H. pylori strains possessing the cagPAI activate epithelial
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cell lines to express pro-inflammatory cytokine interleukin-8 (IL-8) and cag+-strains
are associated with high levels of epithelial cell IL-8 expression (Crabtree et al., 1995;
Peek et al., 1995). A serological response to the CagA-protein (an elevated level of
CagA antibodies) is strongly predictive that a person is carrying a CagA-positive H.
pylori strain (Blaser et al., 1995).
Cytotoxin VacA encoded by the gene vacA is another well-known virulence factor
(Leunk, 1991). It is associated with peptic ulcer and adenocarcinoma. The gene vacA
is present in all strains, but due to several alleles (Atherton et al., 1995) various
amounts of toxins are produced and about half of H. pylori strains secrete the toxin
VacA. Genotype s1m1 is the most virulent genotype of vacA and it is associated with
the cagA positive genotype (Kusters et al., 2006).  There are also other putative
virulence factors. The expression of H. pylori outer inflammatory protein A (OipA) is
associated with duodenal ulceration and gastric cancer (Robinson et al., 2007).
Duodenal  ulcer  promoting  gene  A (dupA) is associated with duodenal ulceration in
patients from South Korea, Japan, and Colombia, but seemed to protect against gastric
cancer in these populations (Robinson et al., 2007). Expression of Blood group
antigen binding adhesion A (BabA) increases the association of cag+ strains with
duodenal ulceration and gastric cancer in some people (Robinson et al., 2007).
HOST RESPONSE TO H. PYLORI
H. pylori colonisation in human stomach usually occurs in childhood, but in most
subjects the infection persists lifelong without an effective treatment.  All infected
individuals develop an inflammatory and immune response to the bacterium, but the
response is not able to cure the infection.  According to self inoculation studies in
adults, acute H. pylori infection is usually symptomatic, creating epigastric
discomfort, nausea, malaise, belching and halitosis, and the symptoms usually resolve
within two weeks (Marshall et al., 1985; Morris and Nicholson, 1987; Sobala et al.,
1991). Histologically, an acute infection produces a heavy neutrophilic infiltration and
a gradual infiltration of inflammatory cells of all classes, predominantly lymphocytes,
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which persists, and a transient hypochlorhydria (Marshall et al., 1985; Morris and
Nicholson, 1987; Sobala et al., 1991). Since spontaneous cure of the infection is rare
(Valle et al., 1996; Kosunen et al., 1997) the infection proceeds to chronic gastritis in
most individuals, characterized predominantly by lymphocytes.
The infection induces an immunological response with circulating antibodies, which
is unable to eradicate the bacterium from the gastric mucosa. Most helicobacter-
infected subjects have specific circulating IgG antibodies, but systemic IgA antibodies
for H. pylori are  less  common  and  are  elevated  in  approximately  two-thirds  of
infected subjects (Kosunen et al., 1992). Of infected individuals, 2-7% show an
elevated IgA level alone (Kosunen et al., 1992; Kosunen et al., 1997; Jaskowski et al.,
1997). The prevalence rates of IgG and IgA antibodies increase by age (Kosunen et
al., 1989; Andersen et al., 1996). Occurrence of specific IgM antibodies is especially
associated with new infections with H. pylori (Andersen et al., 1996).  The clinical
importance of the IgA antibody response during H. pylori infection is emphasized
when considered in association with earlier findings showing an association between
H. pylori IgA and peptic ulcer disease, gastric cancer (Aromaa et al., 1996; Kosunen
et al., 2005) and a CagA-positive infection (Rautelin et al., 2000).
The  immune  response  to H. pylori includes release of pro-inflammatory and
antibacterial factors and infiltration of all classes of immune effector cells in the
gastric mucosa. The pro-inflammatory cytokine IL-8 recruits lymphocytes and
neutrophils, and interleukin 1ß (IL-1ß) is responsible for activation of macrophages
and polymorphonuclear leukocytes (Robinson et al., 2007). In addition, IL-1ß is a
potent inhibitor of acid secretion (Kusters et al., 2006).  There is a life-long persisting
local and systemic acquired humoral and cell-mediated response to H. pylori.  IL-10-
producing T-cells are regarded to be essential in the control of the inflammation
(Kusters et al., 2006). The T-cell response is mainly of Th 1 type. It is suggested using
animal models that Th 1 differentiation is important in pathogenesis of the infection
(Robinson et al., 2007).
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EPIDEMIOLOGY OF H. PYLORI INFECTION
1. Geographical distribution and the prevalence of H. pylori infection.
The cohort phenomenon.
Infection with H. pylori is  worldwide.  The  prevalence  of H. pylori varies between
countries with large differences between developed and developing countries
(Mégraud, 1993; Talley et al., 1993).  In developing countries the prevalence of H.
pylori infection is much higher than in developed countries, and the epidemiology of
the infection is characterised by a rapid acquisition rate of the infection so that even
80% of the population acquires the infection by the age of 20 (Graham et al., 1991a).
Low socioeconomic status and close person-to-person contact increase the likelihood
of contracting this infection and also in developed countries most of the infected
people have got the infection in childhood (Webb et al., 1994).  The prevalence rates
of the infection increase with age in all populations (Mégraud, 1993). This has been
explained by the persistence of childhood H. pylori infections, which have decreased
gradually since the early 1900s: the so-called birth-cohort phenomenon (Parsonnet et
al., 1992; Banatvala et al., 1993a; Sipponen et al., 1996; Kosunen et al., 1997).  In
developed countries the acquisition rate of new infections in adults is estimated to be
less than 3% per 10 years (Mégraud, 1993; Kosunen et al., 1997).  The prevalence of
the  infection  varies  between  subpopulations  in  the  same  country  (Graham  et  al.,
1991b; Breuer et al., 1996; Everhart et al., 2000).  In Finland the age-adjusted
seroprevalence rate in adult population was 34% in 1994 (Kosunen et al., 1997). The
seroprevalence of the infection was 5.6% in Finnish children aged 2 to 20 years,
among whom the  majority  of  new infections  were  acquired  before  the  age  of  seven
years (Rehnberg-Laiho et al., 1998), while the prevalence was 66% in Finnish
centenarians (Rehnberg-Laiho et al., 1999).
2. Changing prevalence of H. pylori infection
The  prevalence  of H. pylori infection is steadily declining in developed countries
(Rehnberg-Laiho et al., 2001; Malaty, 2007). In countries, where living standards
have rapidly improved, the prevalence of H. pylori infection in children has
17
dramatically decreased. In Estonia, the age standardized seroprevalence rate in
children decreased from 42.2% in 1991 to 28.1% in 2002 (p = 0.0002) during the 11-
year period of profound socioeconomic changes in Estonia. Stratified analysis by the
age-groups demonstrated that a statistically significant decrease in seroprevalence
occurred in children aged 0.5-5 years (p < 0.005) and in children aged 6 to 10 years (p
< 0.05) (Oona et al., 2004).  In Russia results from two cross-sectional studies among
children in St. Petersburg demonstrated, how the prevalence among children younger
than 5 years of age decreased from 30% in 1995 to 2% a decade later in the same age-
group (p = 0.001) (Malaty, 2007), indicating that improvements in the standard of
living had resulted in a marked reduction in H. pylori transmission, according to the
author.
3.  Social  class  and  living  conditions  as  risk  factors  for H. pylori
infection
Low socioeconomic status and crowded living conditions are risk factors for
acquisition of the infection in early childhood (Malaty and Graham, 1994; Everhart et
al., 2000; Koch et al., 2005; Bures et al., 2006). The prevalence of H. pylori infection
is inversely related to socioeconomic status in childhood (Graham et al, 1991b)
irrespective of the present social class (Malaty and Graham, 1994). Occupation,
family income level and living conditions in childhood home are parts of a same
socioeconomic complex explaining the risks of becoming infected. For populations in
which the social class is homogenous, the density of living conditions is the most
significant risk factor (Malati et al., 1996).
4. Transmission of H. pylori
Transmission of H. pylori infection has been addressed through prevalence studies
within families, detection in fecal and oral environments, detection in environments,
and direct inference from strain similarity (Delport and Merwe, 2007).  Especially in
developing countries, the low quality of drinking water or a lack of hot tap water have
been suggested to contribute to transmission of the infection. H. pylori has been
identified in drinking water (Schauer et al., 1995). In addition, municipal water supply
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has been suggested for an infection route (Klein et al.,1991) and a transmission via
uncooked vegetables treated with sewage has been proposed (Hopkins et al., 1993).
Transmission via inadequately disinfected endoscopy equipment has been
demonstrated (Stone, 1999). However, it appears likely that H. pylori is transmitted
from person-to-person. Comparison of DNA fingerprints provides evidence for
intrafamilial transmission of the infection (Bamfort et al., 1993). Especially an
infected mother is found to be a risk factor for acquiring the infection in childhood
both in a developing country and in a developed country (Aguemon et al., 2005; Kivi
et al., 2005). In Sweden, infected siblings were found to be a risk factor for acquiring
the infection (Kivi et al., 2005). The possible person-to-person transmission routes are
gastro-oral, oral-oral and fecal-oral routes, but it is not clear which one is the
predominant way for transmission (Banatvala et al., 1993b; Parsonnet et al., 1999;
Song et al., 2000).
H. PYLORI ASSOCIATED DISEASES
1. Gastritis
After the acute phase, most of the infected individuals are not able to clear H. pylori
from the stomach and gastritis progresses to chronic gastritis. The location of H.
pylori colonization in the stomach varies between patients. The commonest pattern of
gastritis is a mild pangastritis, which does not markedly change gastric physiology.
Corpus predominant gastritis is associated with gastric atrophy, hypochlorhydria and
an increased risk of gastric cancer. An antral predominant gastritis is associated with
high acid secretion and an increased risk of duodenal ulcer disease (Loched and El-
Omar, 2007). The natural history of H. pylori infection depends on the acid secretion
capacity in host. In the case of a low secretory capacity, H. pylori is able to colonize a
wide niche towards the corpus which leads to corpus gastritis and inhibition of  acid
secretion, which is mediated by H. pylori induced inflammatory cytokines.
Consequently, gastritis proceeds to atrophic gastritis, which causes the development
of more permanent morphological changes in gastric mucosa (Loched and El-Omar,
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2007). In patients with antral-predominant gastritis and a high acid output, gastric
metaplasia is likely to develop in the duodenum increasing the risk of peptic duodenal
ulcer. However, the use of acid suppressing medicines like PPIs can shift the pattern
of gastritis from antral to a corpus-predominant type which induces a higher risk of
developing gastric atrophy (Loched and El-Omar, 2007).
After successful eradication therapy, active inflammation rapidly resolves (Valle et
al., 1991), but mild chronic gastritis may persist in some individuals for many years
(Veijola et al., 2007).
2. Atrophic gastritis
Atrophic gastritis is a late consequence of H. pylori infection in about one third or half
of infected individuals (Siurala et al., 1985; Kuipers et al., 1995; Valle et al., 1996;
Lauwers, 2003). The development of atrophy takes approximately 20 years (Siurala et
al., 1968).  Loss of mucosal glands leads to failures in secretory functions of the
gastric mucosa. Chronic atrophic gastritis has been classically divided into type A and
type B. Autoimmune-type A atrophic gastritis is associated with pernicious anaemia
caused by malabsorption of vitamin B12, and the atrophy is situated in the corpus and
fundus leading to a decrease in the number of glands and a decrease of PGI and acid
output  (Varis  et  al.,  1979a),  whereas  serum  gastrin  levels  are  elevated  (Varis  et  al.,
1979b).  In type B atrophic gastritis the atrophy is predominantly located in the
antrum mucosa and results in a loss of antral glands and the number of gastrin-
secreting G cells and somatostatin-secreting D cells (Sipponen et al., 1990). Intestinal
metaplasia is a common finding in atrophic gastritis (Lauwers, 2003). H. pylori
infection, atrophic gastritis and intestinal metaplasia are well-known risk factors and
precursors for gastric cancer (Sipponen et al., 1985; Kuipers et al., 1995; Kuipers et
al., 1996; Lauwers, 2003).
2.1. The role of H. pylori in atrophic gastritis
The antrum predominant type B atrophic gastritis is in most cases caused by H. pylori
infection (Kuipers et al., 1995). The role of H. pylori in the autoimmune-type A
atrophic gastritis is controversial (Varis et al., 1993; Kuipers et al., 1997; Clayes et al.,
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1998).  In recent years, the classical division of type A and type B has been
impugned, due to accumulating data suggesting that corpus atrophy is caused by H.
pylori associated autoimmune process (Valle et al., 1996, Annibale et al., 2002;
Bergman  et  al.,  2005).   However,  the  role  of H. pylori as a trigger in autoimmune
gastritis is debatable (Malfertheiner et al., 2007).
The development of atrophic gastritis can be prevented by H. pylori eradication, and
atrophic changes on gastric mucosa can turn to normal after successful eradication
(Kokkola et al., 2002). In advancing atrophic gastritis the helicobacter colonization on
the gastric mucosa decreases. The detection of H. pylori infection can be
underestimated, if only biopsy-based diagnostic methods are used (Kokkola et al.,
1998).
2.2. Histological classification of gastritis and atrophy
Mucosal atrophy can be detected by histology or blood tests. Microscopic
examination of gastric biopsy specimens reveals the presence, the topographic
location and the grade of mucosal atrophy. Gastritis is most commonly classified
according to the Sydney System using the elements of morphology, topography and
etiology (Price, 1991; Dixon et al., 1996). The morphologic features are graded into
mild, moderate and severe. The graded characteristics are chronic inflammation,
activity, atrophy, metaplasia, and H. pylori. The microscopical criteria for mild,
moderate, and severe atrophy are a loss of the glands less than 30%, 30-60%, and
more than 60%, respectively (Price, 1991). The topographic distribution of chronic
gastritis is considered as antrum gastritis, corpus gastritis and pangastritis.
2.3. Serum tests in assessment of atrophy and autoimmunity
Two immunologically distinct groups of pepsinogens exist in the gastric mucosa: PGI
is derived from the fundic glands and PGII from the chief and mucus neck cell
components of the fundic glands, pyloric glands in the antrum, and Brunner glands in
the duodenal bulb. In atrophic gastritis the number of fundic glands declines leading
to a decline in serum PGI values without changes in the concentration of serum PGII.
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Low serum PGI concentration and low ratio of serum PGI/PGII can be used to detect
atrophic changes in the corpus (Samloff et al., 1982).
Gastrin is secreted by the G cells in the antral glands. It activates parietal cells to
secrete acid. Several forms of gastrin can be measured in blood and over 90% of
circulating gastrin consists of gastrin-34 and gastrin-17. The former is responsible for
the basal and continuous acid secretion, and gastrin-17 accounts for the secretion
which is stimulated by food ingestion (Miller, 1999). In patients with atrophic corpus
gastritis the serum gastrin levels are elevated (Kekki et al., 1991), whereas low serum
gastrin-17 reveals atrophic antrum gastritis (Hallissey et al., 1994; Oksanen et al.,
2000; Vaajanen et al., 2003).
Parietal cell antibodies (PCA) are detected in about 60% of patients with atrophic
gastritis and in over 90% of patients with pernicious anaemia (Whittingham and
Mackay, 2005).  Antibodies against gastric secreted intrinsic factor, which is
produced by parietal cells and contributes to absorption of B12-vitamin, have been
found in 50 to 70% of patients suffering from pernicious anaemia (Whittingham and
Mackay, 2005).
A  test-combination  of  serum  PGI,  gastrin-17,  and H. pylori antibodies seems to
establish with high sensitivity and specificity the diagnosis of gastritis and the
presence and location of atrophic changes in gastric mucosa (Sipponen et al., 2002).
3. Dyspepsia
Dyspepsia has several definitions. Formerly it has been proposed to classify dyspepsia
into symptom subgroups of ulcer-like dyspepsia, dysmotility-like dyspepsia, reflux-
like dyspepsia, and unspecified dyspepsia (Talley et al., 1992). According to the
Rome II criteria, dyspepsia is defined as upper abdominal pain or discomfort (Talley
et al., 1999).  In a random sample of 4581 Danes aged 30-60 years, the prevalence of
dyspepsia within the past 12 months was 54% among men and 47% among women
(Kay and Jørgensen, 1994). In Sweden, the prevalence of dyspepsia during the
preceding three months was highest among young women decreasing from 26%
22
among those aged 20-34 years to 14% among those aged 65-79 years, while the
prevalence decreased from 17% to 7% among men of corresponding age (Agréus et
al., 1994). Depending on the age of the population studied, between 33% and 55% of
the patients suffering from dyspepsia are infected with H. pylori (Bernersen  et  al.,
1992; Agréus et al., 1995; McColl et al., 1997).  Reasons for consulting a physician
due to dyspepsia are multifactorial, but H. pylori infection, lower socioeconomic
status, frequent or severe symptoms, and increasing age are reported to be
independent predictors of seeking medical help (Ford et al., 2007). Also in Finland
increasing age has been connected with the consultation frequency regarding
dyspepsia (Heikkinen et al., 1996).
A ‘test-and-treat’ strategy study on uninvestigated dyspepsia in Canada demonstrated
a significant symptom benefit at 12 months with H. pylori eradication (Chiba et al.,
2002). The effect of eradication treatment on symptoms and related health costs of H.
pylori infected dyspepsia patients has been actively studied. The benefit achieved in
symptoms and health costs seems to correlate to the length of the follow-up, since
significant reductions in total dyspepsia-related health care costs were reported after
10 years follow-up (Ford et al., 2005). It has been calculated that about 10 % of the
patients suffering from functional dyspepsia could benefit from successful H. pylori
eradication treatment and 14 patients would have to be treated to cure one case
(Moayyedi et al., 2005), and that 30 individuals with H. pylori would have to be
treated to prevent one person consulting their doctor for dyspepsia during two years
follow-up (Lane et al., 2006). According to the latest European guidelines, H. pylori
‘test and treat’ is appropriate for patients with uninvestigated dyspepsia
(Malfertheiner et al., 2007).
4. Peptic ulcer
Soon after the detection of H. pylori the bacterium was associated with duodenal and
gastric ulcers (Marshall and Warren, 1983; Marshall and Warren, 1984). In Western
countries, duodenal ulcers are about four-fold more common than gastric ulcers, while
elsewhere the gastric ulcers are more common (Kusters et al., 2006).  The antral
predominant form of active chronic gastritis is associated with duodenal ulcer disease
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(Dixon, 2000).  The role of H. pylori in peptic ulcer disease is generally accepted
(Blaser, 2004) and eradication therapy is strongly recommended (NIH Consensus
Development Panel, 1994). Approximately 95% of the duodenal ulcers are caused by
H. pylori infection and the recurrence of the ulcers is prevented by successful
eradication of H. pylori, while about 70% of the gastric ulcers, commonly caused also
by NSAIDs, is associated with H. pylori infection  (Ford  et  al.,  2004).   The
relationship between H. pylori infection and NSAIDs in gastroduodenal ulcers is
complex, since H. pylori and NSAIDs independently and significantly increase the
risk of peptic ulcer bleeding by 1.8 and 4.9-fold, respectively, and the risk is increased
by 6.1-fold when both the factors are present (Huang et al., 2002). In Finland, the
prevalence of H. pylori associated peptic ulcer disease has declined due to decreasing
prevalence and active treatment of the infection (Veijola et al., 2005a; Koivisto et al.,
2005).
5. Mucosa associated lymphoid tissue lymphoma
H. pylori is associated with the development of the majority of primary low grade
gastric MALT lymphomas (Wotherspoon et al., 1991; Lochhead and El-Omar, 2007).
In this rarely occurring disease, 62% of the patients with a low grade gastric MALT
lymphoma have demonstrated a complete remission after successful eradication
(Malfertheiner et al., 2007).
6. Gastric cancer
H. pylori infection has been classified as a first class carcinogen for gastric cancer
(International Agency for Research on Cancer, 1994) and it is estimated that 60-90%
of gastric cancers are associated with H. pylori (Malfertheiner et al., 2005). In
Finland, declining local H. pylori prevalence rates seemed to predict the declining
local incidences of gastric cancer after a median latency of 20 years (Rehnberg-Laiho
et al., 2001). Of the common patterns of gastritis, the corpus predominant gastritis is
associated with hypochlorhydria, gastric atrophy and intestinal metaplasia widely
accepted to be precursors for gastric cancer, and an increased risk or gastric cancer
(Kuipers et al., 1995; Valle et al., 1996; Lauwers, 2003; Loched and El-Omar, 2007).
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It has been suggested that H. pylori eradication for gastric cancer prevention in
populations at risk should be evaluated (Forman and Graham, 2004; Malfertheiner et
al., 2007). An important determinant in cancer prevention is the so-called ‘point of no
return’, at which the premalignant morphological changes in gastric mucosa are
irreversible.  In  reports  on  the  effect  of H. pylori eradication on the development of
gastric cancer, the development of cancer was prevented only in patients, who had no
atrophic gastritis, intestinal metaplasia or dysplasia before eradication therapy (Wong
et al., 2004).
7. Extragastric diseases
The  possible  role  of H. pylori infection in extragastric diseases has been actively
studied. The latest European guidelines for the management of H. pylori infection
recommend searching and treating for H. pylori infection in patients suffering from
iron deficiency anaemia or idiopathic thrombocytopenic purpura (Malfertheiner et al.,
2007), whereas H. pylori has no proven role in other extragastric manifestations.
DIAGNOSTIC METHODS FOR H. PYLORI INFECTION
The  accuracy  of  a  diagnostic  test  is  strongly  dependent  on  the  prevalence  of  the
infection (Leodolter at al., 2001; Oksanen et al., 2001). In areas of low H. pylori
prevalence, the diagnostic test used can demonstrate a lower positive predictive value
resulting in an increased number of false positive test results. No single test can be
considered a gold standard for the detection of H. pylori infection, since all tests have
their limitations, which depend on the clinical situation and the local facilities (Cutler
et al., 1995).
There are several invasive and non-invasive methods available for the diagnosis of H.
pylori infection. The invasive methods necessitate taking of gastric biopsies with the
aid of gastroscopy. The clinical situation of the patients determines whether a
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gastroscopy is needed or whether a non-invasive method is more preferable
(Malfertheiner at al., 2002; Pikkarainen et al., 2002).  Gastroscopy is not needed for
the  diagnosis  of H. pylori infection but if the patient is gastroscopied for clinical
reasons, gastric biopsies can be used for the diagnosis of H. pylori as well.
1. Invasive methods
1.1. Rapid urease test
In rapid urease tests (RUTs), the urease of H. pylori splits the urea in a gel or liquid
and produces ammonia, which causes a rise in pH. This is demonstrated by a change
in  colour  from  yellow  to  read  in  test  medium  with  the  aid  of  an  indicator  within  3
hours with the newer tests (Marshall et al., 1987; Tseng et al., 2005). There are both
in-house and commercial RUTs available. The accuracy for RUTs in detecting H.
pylori is considered high demonstrating sensitivities and specificities exceeding 90%
(Laine et al., 1996; van Keeken et al., 2006).
1.2. Histology
The silver staining of antral biopsies has been shown to be most accurate in detecting
H. pylori infection in histology, compared to serological tests and UBTs (Cutler et al.,
1995). In addition to insensitive haematoxylin-eosin staining, the use of highly
sensitive modified Giemsa staining is recommended for clinical use for the detection
of H. pylori (Madan et al., 1988; Dixon et al., 1996).
The histological findings are classified by the Sydney System (Price, 1991; Dixon et
al., 1996), in which the presence of H. pylori is graded from 0 to 3. According to this
system, two biopsies from both antrum and corpus are needed for histology. The
diagnostic and grading criteria suggested by the Sydney System have been well
accepted by histopathologists (Andrew et al., 1994; el-Zimaity et al., 1996). However,
the results are dependent on the experience of the pathologist (Metz et al., 1998), the
number of biopsies taken (van IJzendoorn et al., 2005), and the density of H. pylori in
gastric mucosa (Testoni et al., 2002). With an experienced pathologist, the sensitivity
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and specificity of histological examination in detecting H. pylori infection were 94%
and 100%, respectively, as compared to a combination of gastritis and elevated H.
pylori antibodies (Oksanen et al., 1998).
1.3. Culture and antimicrobial susceptibility
The sensitivity of culture is usually lower than that of other methods and is influenced
by the transport medium, time, and the experience of the laboratory personnel (de
Boer, 1997; Pérez-Pérez, 2000). H. pylori is  relatively  slow-growing  and  culture
plates should be incubated for 12 days (Rautelin et al., 1997). Following an incubation
time of 12 days, the sensitivity and specificity of culture in detecting H. pylori
infection were 77% and 100%, respectively, as compared to a combination of gastritis
and elevated H. pylori antibodies (Oksanen et al., 1998).
Culture offers an opportunity for testing the antimicrobial susceptibility, which is
clinically important, since H. pylori develops resistance against metronidazole and
clarithromycin which are commonly used in eradication treatments. It is also possible
to further characterize the H. pylori strains isolated, although the detection of
virulence factors is not recommended in clinical practice. In clinical use, culture of H.
pylori and antimicrobial susceptibility test are indicated after one or two failed
eradication treatments (Mégraud and Lehours, 2007).
1.4. Molecular methods
The polymerase chain reaction (PCR) is a technique in which predetermined
fragments of bacterial DNA are amplified. It is seldom used in clinical practice. For
scientific purposes, it enables to determine virulence genes like cagA and




2.1.1. Enzyme immunoassay for H. pylori antibodies
EIA is the most commonly used serological test for detecting antibodies to H. pylori,
since it is reliable, simple, and inexpensive. In EIA-based tests the antigen is adsorbed
onto plastic support, usually a 96-well polyvinyl or polystyrene microtitre plate.
Diluted serum is incubated with the immobilized antigen and antigen-antibody-
complexes are formed. The complexes are detected using an enzyme-conjugated
(anti-human) antibody. The amount of enzyme, which is representing the amount of
bound antibodies, is visualized using a chromogenic enzyme substrate.
The special role of EIA serology has recently been emphasized compared to other
diagnostic  tests;  the  usefulness  of  this  method  is  not  affected  by  prior  use  of  PPIs,
ulcer bleeding, or the diminished number of helicobacters on the gastric mucosa
(Malfertheiner et al., 2007). With EIA it is possible to measure H. pylori antibodies of
different immunoglobulin classes and to make quantitative determinations.
Quantitative serological assays can be used both in the diagnosis of the infection and
in the follow-up after eradication treatment. Using serology as a follow-up method
after treatment requires taking a pre-treatment serum, a post-treatment serum four to
six months after therapy and testing the samples in parallel in the same assay to
determine the decline of antibody titres. The criterion for successful eradication is an
antibody titer decline of at least 40% four to six moths after treatment (Kosunen et al.,
1992; Lerang et al., 1998; Rautelin and Kosunen, 2004).
There are several commercial serological kits available (Lahei et al., 1998). The best
commercial kits have shown sensitivities and specificities greater than 95%; the
sensitivity and specificity of the commercial tests has varied between 60 and 100%
(Feldman et al 1995; Lahei et al 1998).  The best quantitative Finnish commercial and
in-house EIA-tests detecting H. pylori IgG antibodies show sensitivities of 99% and
specificities of 97-98% (Oksanen et al., 1998) and of these tests, the commercial
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Pyloriset EIA-G (Orion Diagnostics, Espoo, Finland), which is widely used in
Finland, proved to have the best accuracy in a comparison of several commercial
EIA-assays testing the same sera in several laboratories in Europe (Feldman et al.,
1995).
The serologic tests may, however, demonstrate a lower performance if the population
has been actively treated for H. pylori infection, since after successful H. pylori
eradication therapy the antibodies decline slowly to normal levels. The antibodies
declined below the cut-off level only in 28% of successfully treated patients after one
year (Lerang et al., 1998), and after five years, 33% of individuals still demonstrated
elevated antibody levels after successful eradication therapy (Veijola et al., 2007). It
has been recommended that antibody assays should be evaluated locally (Feldman et
al., 1995; Hernbrink and van Doorn., 2000). In addition to the properties of the
serology kit used, the reference method determining active H. pylori infection, the
selection of patients and variations in the antigenic properties of the bacterial strains
can explain the variation in sensitivity and specificity between different EIA tests
(Herbrink and van Doorn, 2000; Laheij et al., 1998).
2.1.2. Near patient tests
Point-of-care tests are mostly whole blood tests. They are not currently recommended
because of low accuracy (Malfertheiner et al., 2007).
2.1.3. Immunoblot assay
In immunoblot assays antigens are separated by electrophoresis according to their
molecular weight and transferred onto absorbent paper in order to react with specific
antibodies. The antibodies are detected by a conjugate and substrate as in EIA.
Immunoblots are not used in clinical practice but could be used in special
circumstances for instance to detect CagA antibodies (Nilsson et al., 1997).
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2.2. Urea breath test
The  UBT  is  based  on  the  ability  of H. pylori on the gastric mucosa to hydrolyse
ingested isotope-labelled urea by urease enzyme which produces isotope-labelled
CO2. The labelled CO2 diffuses then into the blood and is excreted by the lungs and
can be measured in the exhaled air. Both radioactive 14C and non-radioactive 13C-
labelled urea have been used (Marshall and Surveoyr, 1988; Graham et al., 1987).
Measurement of the 13C isotope, which is more commonly used, is performed by
isotope ratio mass spectrometry, non-dispersive isotope-selective infrared
spectrometry or a laser assisted ratio analyser.
UBT has proved to be highly accurate both in diagnosing H. pylori infection and in
the follow-up after treatment demonstrating a sensitivity and specificity exceeding
95% and is widely used (Gisbert and Pajares, 2004a).  However, preceding
antimicrobial or PPI-treatment, bleeding ulcer, and conditions associated with low
bacterial density on gastric mucosa can lead to false negative test results
(Malfertheiner et al., 2007).
2.3. Stool antigen tests
Tests detecting H. pylori antigens  in  stool  samples  are  based  on  monoclonal  or
polyclonal antibodies. It is necessary to store the stool samples at -20°C until
analysed.  In  a  systematic  review  of  89  studies  (Gisbert  and  Pajares,  2004b),  the
sensitivity and specificity of stool antigen tests were 91% and 93%, respectively. The
monoclonal tests have performed well both in primary and post-therapy diagnosis
(Veijola et al., 2005b).
2.4. Other tests
EIA-based salivary antibody tests have generally demonstrated quite low diagnostic
accuracy (Kabir, 2003) and they have no current role in patient management
(Malfertheiner et al., 2007).   The commercial tests for detecting H. pylori antibodies
in urine are based on EIA (Katsuragi et al., 1998) or rapid immunochromatographic
methods (Wu et al., 2001). The EIA-based urine test (Urinelisa) showed only modest
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accuracy (sensitivity 63-89% and specificity 68-97%), when evaluated in multicenter
studies in children (Mégraud et al., 2005) and in adults (Leodolter et al., 2003).  An
immunochromatographic test (Rapirun) showed a sensitivity of 82% and a specificity
of 83% in adults (Leodolter et al., 2003).  The tests for detecting H. pylori antibodies
in urine are not regarded useful in patient management, but can be useful in
epidemiological studies (Malfertheiner et al., 2007).
3. Diagnosis in special situations
3.1. Children
The sensitivity of serological tests based on IgG antibody detection is low in children
younger than six years, but the decline in antibody titres is useful in confirming the
success of eradication treatment in children (Kolho et al., 2002). UBT has proved to
be accurate in children although false positive result may occur in young children
(Kolezko and Feydt-Schmidt, 2001). The performance of stool antigen tests has
proved to be excellent in young children demonstrating accuracy exceeding 95%
(Kolho et al., 2006).
3.2. The elderly
The prevalence of serious diseases increases by age. Consequently, the management
of dyspepsia in the elderly easily includes endoscopic examination with gastric
biopsies, which allows detection of macroscopic and microscopic abnormalities. The
detection of H. pylori is more challenging with the elderly (Salles and Mégraud,
2007), since the prevalence of atrophic gastritis is higher in this age-group than
among younger individuals, which can lead to false negative test results in histology
due  to  a  lower  bacterial  density  on  mucosa.   Serology  is  the  method  of  choice  in
detecting H. pylori infection in the case of atrophic gastritis or other conditions with a
low density of bacteria. However, there is a possibility of false positive test results,
due to slowly declining antibody levels after a cured infection (Veijola et al., 2007).
UBT is regarded to obtain the best performance in the elderly (Salles and Mégraud,
2007).
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3.3. Bleeding peptic ulcer
Successful H. pylori eradication prevents the recurrence of the ulcers among infected
subjects (Ford et al., 2004). H. pylori eradication also prevents effectively rebleeding
in H. pylori infected individuals, while the risk of rebleeding is approximately 50% at
10 years, if the patient is left untreated after ulcer healing (Gisbert et al., 2004c). In
the case of ulcer bleeding, the detection of H. pylori is complicated, since PPIs are
regularly used which with acute ulcer bleeding impairs the sensitivity of biopsy-based
methods and UBT for detecting H. pylori-infection (Malfertheiner et al., 2007). In this
special situation, the role of serology is emphasized as an accurate method to diagnose
H. pylori infection (Malfertheiner et al., 2007).
3.4 Atrophic gastritis
Patients with atrophic corpus gastritis have often positive helicobacter serology, but
their histologic findings often remain helicobacter negative (Karnes et al., 1991;
Testoni et al., 1996; Kokkola et al., 2000). Along with advancing atrophic gastritis the
helicobacter colonization on the gastric mucosa decreases. The diagnosis and
prevalence of H. pylori infection can remain underestimated, if only biopsy-based
diagnostic methods are used.  Due to advanced gastric atrophy, many culture,
histology and breath test negative subjects may still be infected which has been shown
by rapidly falling antibody titres in these patients after eradication therapy (Kokkola
et al., 1998). Serology is sensitive in detecting H. pylori in  the  case  of  atrophy
(Malfertheiner et al., 2007), but the specificity may be lower, since this method does
not differentiate between a current and a past infection; after successful H. pylori
eradication therapy the antibodies decline slowly to normal levels (Veijola et al 2007).
32
GUIDELINES FOR THE MANAGEMENT OF H. PYLORI
INFECTION
1. European guidelines
The first European Guidelines, ‘Current European concepts in the management of
Helicobacter pylori infection. The Maastricht Consensus Report’ was published in
1997 (EHPSG, 1997). It summarized the latest knowledge in the area provided by 63
experts from 19 European countries. The update of the Guidelines, ‘Current concepts
in the management of Helicobacter pylori infection – The Maastricht 2-2000
Consensus Report’ was published in 2000 (Malfertheiner et al., 2000), and the latest
update, ‘Current concepts in the management of Helicobacter pylori infection: the
Maastricht III Consensus Report’ was published in 2007 (Malfertheiner et al., 2007).
Each of the guidelines emphasized special viewpoints, although the themes about
‘how to test’, ‘whom to test’ and ‘how to treat’ were discussed in each report.
1.1. The first Consensus Report
Special  themes  were:  the  role  of  primary  care  physician,  patient  management  level,
and public health issues. Primary care physicians were advised to diagnose H. pylori
infection using UBT or locally validated serology in dyspeptic patients younger than
45 of age and without alarming symptoms, while other dyspeptic patients were
referred to a specialist. A close collaboration and interaction between primary care
physicians (GPs), gastroenterologists and microbiologists was recommended
(EHPSG, 1997).
Strongly recommended indications for eradication therapy were: peptic ulcer disease,
bleeding peptic ulcer, low-grade gastric MALT lymphoma, gastritis with severe
abnormalities, and earlier resection for gastric cancer. Advisable indications were:
functional dyspepsia after full investigation, family history of gastric cancer, long-
term treatment with PPIs for gastro-oesophageal reflux disease (GORD), planned or
existing NSAID therapy, gastric surgery for peptic ulcer, and patient’s wishes.
Uncertain indications were: prevention of gastric cancer, treatment of asymptomatic
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subjects and an extra-alimentary tract disease. The recommended treatment regimens
consisted of triple therapies with metronidazole/tinidazole and clarithromycin,
amoxicillin and clarithromycin, or amoxicillin and metronidazole, all combined with
PPI.
1.2. The second Consensus Report
Special themes were: H. pylori diagnosis and eradication in primary care, indications
for eradication therapy, and prevention of cancer and other H. pylori related
gastroduodenal pathologies.  The GPs were advised to diagnose the infection with
UBT or stool antigen test and always verify the success of the eradication therapy. A
’search-and-treat’ strategy was recommended for peptic ulcer patients on long-term or
intermittent antisecretory therapy (Malfertheiner et al., 2000).
Strongly recommended indications included (in addition to those described in the first
Consensus Report) also atrophic gastritis, post-gastric cancer resection, gastric cancer
in first degree relatives, and patient’s wishes (after full consultation). H. pylori
eradication was considered not to be associated with GORD development. H. pylori
eradication was considered to lead to long-term symptom improvement in a subset of
patients suffering from functional dyspepsia.  Bismuth subcitrate based quadruple
therapy of seven days was recommended for a second course of treatment after a
treatment failure.
1.3. The third Consensus Report
The special themes were: Indications and contraindications for eradication, focusing
on dyspepsia, NSAIDs, GORD, diagnostic tests and treatment of infection, and
prevention of gastric cancer (Malfertheiner et al., 2007).
1.3.1. Dyspepsia, GORD, NSAIDs, and extraintestinal diseases
It was recommended that H. pylori eradication is appropriate for patients infected
with H. pylori and investigated non-ulcer dyspepsia, and H. pylori ‘test-and-treat’ is
appropriate for patients with uninvestigated dyspepsia. The effectiveness of H. pylori
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‘test-and-treat’ was considered low in populations with a prevalence of  < 20% and
empirical acid suppression was considered an equivalent option. It was stated that H.
pylori eradication does not cause GORD, and H. pylori testing and treating should be
considered for patients receiving long-term maintenance treatment with PPIs. H.
pylori eradication was recommended in naïve users of NSAIDs and in the case of
bleeding in patients receiving long-term aspirin treatment.  Related to extraintestinal
diseases it was recommended to search for and treat the infection in patients with
unexplained iron deficiency anaemia and in patients with idiopathic
thrombocytopenic purpura.
1.3.2. Special role of serology
The consensus report emphasized the special role of serology as a diagnostic test in
situations where other tests could be false negative, for example in bleeding ulcers,
gastric atrophy and other conditions of low bacterial density, MALT lymphoma, and
recent or current use of PPIs. However, serology-based point-of-care tests and the
detection of specific H. pylori antibodies in urine or saliva have no current role in the
patient management, according to the report.
It was recommended to confirm H. pylori eradication at least four weeks after
treatment by UBT or a laboratory stool antigen test using monoclonal antibodies.
Culture and antimicrobial sensitivity testing was recommended to be performed
routinely before clarithromycin based treatment, if primary resistance is greater than
15-20%, and after two treatment failures.
1.3.3. Eradication treatment regimens
A triple therapy was recommended including PPI (standard dose) b.i.d.,
clarithromycin (500mg) b.i.d., amoxicillin (1g) b.i.d. or metronidazole (400 or
500mg) b.i.d. for 14 days or for seven days if local studies show that it is effective. In
populations with less than 15-20% clarithromycin resistance, triple therapy including
PPI, clarithromycin, and amoxicillin/metronidazole was recommended. In populations
with less than 40% metronidazole resistance, the use of PPI-clarithromycin-
metronidazole is preferable. Quadruple treatments were considered as an alternative
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first choice treatment. For a second course of treatment, bismuth-containing quadruple
treatments were recommended, if available, or triple therapies including PPI,
amoxicillin or tetracycline, and metronidazole, if bismuth is not available. For rescue
treatment  antimicrobial  susceptibility  testing  should  precede  the  choosing  of  a
treatment regimen, according to the report.
1.3.4. The relation between H. pylori and gastric cancer
It was stated that the global burden of gastric cancer is increasing, predominantly in
developing countries and H. pylori is the most common risk factor for human non-
cardiac gastric cancer. It was stated that the risk for gastric cancer development
depends on bacterial virulence factors and hosts genetic factors, and also
environmental factors contribute to the risk. Eradication of H. pylori prevents the
development of pre-neoplastic changes of the gastric mucosa and has the potential to
reduce the risk of gastric cancer development, and the optimal time for eradication is
before pre-neoplastic conditions (atrophy, intestinal metaplasia) are present, probably
in early adulthood, according to the report. H. pylori eradication for gastric cancer
prevention in populations at risk was recommended to be evaluated and considered.
2. Finnish guidelines
The first Finnish recommendation for the management of H. pylori infection was
published in January 1996 and providing advise as to how to diagnose H. pylori
infection, whom to treat, and what treatment regimens should be used (Färkkilä et al.,
1996). The second Finnish recommendation was published in March 2000 (Suomen
gastroenterologiayhdistys ry, 2000).
2.1. The first Finnish guidelines
According to the first guidelines, it was possible to detect H. pylori by histology, by
culture or RUT of the biopsies obtained during gastroscopy, or by non-invasive
methods using serology or UBT, if available. Strongly recommended indications for
eradication treatment were active or nonactive peptic ulcer disease, while advisable or
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uncertain  indications  were  the  use  of  NSAIDs and  functional  dyspepsia  with  severe
symptoms after gastroscopy, according to the guidelines (Färkkilä et al., 1996).
The recommended treatment regimens included amoxicillin (1g) b.i.d. (or tetracycline
(500mg) q.i.d. for those allergic to amoxicillin), metronidazole (400mg) t.i.d. and PPI
(standard dose) b.i.d. for seven days. The second course of treatment included
tetracycline (500mg) q.i.d. or amoxicillin (1g) b.i.d., metronidazole (400mg) t.i.d.,
bismuth  subcitrate  (240mg)  and  PPI  (standard  dose)  b.i.d.  for  seven  days,  or
amoxicillin (1g) b.i.d. or tetracycline (500mg) q.i.d., clarithromycin (250mg) b.i.d.
and  PPI  (standard  dose)  b.i.d.  for  seven  days.  The  success  of  treatment  was
recommended always to verify performing gastroscopy with biopsies in gastric ulcers,
and by using UBT, serology, or gastroscopy in other patients.
2. 2. The second Finnish guidelines
According to the 2000 guidelines, if gastroscopy is indicated for clinical reasons,
gastric biopsies (two biopsies from antrum and two from corpus for histologic
examination) can be used for the diagnosis of H. pylori infection. An active ulcer or
another condition requiring immediate eradication treatment indicates taking
additional biopsies for RUT, and two or more previous courses of eradication
treatment indicates taking additional biopsies for culture.  If gastroscopy is not
needed, 13C-UBT, quantitative serology or a stool antigen test is the method of choice
for the diagnosis of H. pylori infection.   It  is  recommended to  verify  the  success  of
treatment by UBT or quantitative serology (Suomen gastroenterologiayhdistys ry,
2000).
The indications for eradication therapy are almost similar to those in the third
European Consensus Report. The Finnish indications include peptic ulcer disease with
or without ulcer bleeding, gastric surgery for peptic ulcers, gastric surgery for
localized gastric cancer or premalignant lesion, MALT lymphoma, atrophic gastritis,
dysplasia, gastric cancer in a close relative, new dyspepsia, functional dyspepsia, and
the use of NSAIDs. Screening for H. pylori infection among asymptomatic
individuals or in extragastric diseases is not recommended, according to the Finnish
guidelines.
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The recommended treatment regimen for adults consists of PPI (standard dose) or
ranitidine-bismuth (400mg), amoxicillin (1g) and clarithromycin (500mg) b.i.d. for
seven days, or PPI (standard dose) or ranitidine-bismuth (400mg), metronidazole
(400mg), and clarithromycin (250mg) b.i.d. for seven days, or ranitidine-bismuth
(400mg) b.i.d., metronidazole (250mg) q.i.d. or (500mg) t.i.d., and tetracycline
(500mg) q.i.d. for seven days. It is not recommended to use metronidazole, if the local
metronidazole resistance is over 30%. After two failed treatment regiments, culture
and testing for the antimicrobial susceptibility are indicated, according to the
guidelines.
The second Finnish guidelines were updated in online in 2002
(http://www.terveysportti.fi). According to the updated guidelines, the recommended
treatment regimen for adults consists of PPI (standard dose), amoxicillin (1g) and
clarithromycin (500mg) b.i.d. for seven days, or ranitidine-bismuth (400mg),
amoxicillin (1g) and clarithromycin (500mg) b.i.d. for seven days. The recommended
second course of treatment includes ranitidine-bismuth (400mg) b.i.d., metronidazole
(400mg) t.i.d. and tetracycline (500mg) q.i.d. for seven days. After two failed
treatment regiments, culture and testing the antimicrobial susceptibility are indicated.
SCREENING AND TREATING FOR H. PYLORI
1. Is H. pylori infection appropriate for screening?
In general, an ideal screening programme should have following prerequisites for the
disease  (WHO,  1968):  1)  The  treatment  improves  the  prognosis  if  it  is  given  at  an
early state of the disease. 2) The disease is common enough and the consequences are
significant (mortality,  invalidity,  morbidity).  3) It  is  possible to detect  the disease at
an early stage. 4) There is a long delay from the beginning of the disease to the
clinical symptoms. Infection with H. pylori is mostly acquired in childhood. It causes
life long bacterial infection on the gastric mucosa and causes a progressive damage of
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the mucosa which can lead to peptic ulcer disease or premalignant and malign
conditions. It usually does not heal without specific antimicrobial treatment. The
disease prerequisites for an ideal screening programme are fulfilled, since H. pylori
eradication improves dramatically the prognosis of peptic ulcer disease and prevents
the development of gastric cancer, if it is given at early stage, before the outcome of
premalignant conditions, and it also improves the prognosis in some of the persons
suffering from dyspepsia. H. pylori infection is one of the most common infections in
the word, although the prevalence of the infection is rapidly declining in the Western
world and the consequences are severe. It is possible to diagnose the infection at early
stage, and there is usually a long delay to the clinical outcomes.
Furthermore, an ideal screening programme should have following prerequisites for
the test (WHO, 1968): 1) The test demonstrates a high sensitivity and specificity. 2)
The  test  is  cheap,  simple,  and  is  suited  to  large  populations.  3)  The  test  is  safe  and
acceptable. 4) The test is easy to repeat. 5) The possible further studies should not be
expensive or unsafe. Locally validated H. pylori antibody assays with a high accuracy
fulfil the test prerequisites for an ideal screening programme, since they are cheap,
simple, safe, acceptable, suitable also for large populations, and easy to repeat. More
expensive urea breath tests are also suitable for this purpose. If needed, an UBT, stool
test or gastroscopy already common in clinical use can be utilized for possible further
testing.
2. Recruitment for clinical trials
Recruitment of an adequate number of participants is essential to achieve a successful
completion  of  a  clinical  trial.  Sometimes  studies  report  the  need  to  extend  the
recruitment period to achieve a large number of participants to reach statistically
significant results (Lovato et al., 1997). It is important to plan carefully and carry out
a pilot study before the trial and if needed alter the existing plans for requirement
strategies according to the results of piloting. Recruitment of diverse populations such
as ethnic minorities, men, the elderly and individuals aged less than 45 years have
appeared to be challenging according to previous reports (Slattery et al., 1995; Eachus
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et al., 1996;  Lovato et al., 1997). In addition, material deprivation has been associated
with lower participation rates (Lane et al., 2002).
In recruitment the using of national population registries, national disease related
registries, local databases containing lists of patients or other databases is utilized.
Screening for potential participants at an occupational site offers a possibility to easily
contact a large number of individuals (Lovato et al., 1997). Invitation by mail is a
relatively low-cost approach for contacting large numbers of potential participants
(Bjornson-Benson et al., 1993). Personalized letters and a coordinated media-
campaign have improved the efficiency and effectiveness of this strategy (Bjornson-
Benson et al., 1993). Recruiting participants using announcements in media is also
possible.
3. Reasons for non-compliance in screening
In considering the effectiveness of a screening programme, it is important to take into
account non-compliance. According to a systematic review, barriers to participation in
randomized controlled trials were divided into clinician barriers and patient barriers
(Ross et al., 1999). The clinician barriers included: time constraint, lack of staff and
training, worry about the impact on the doctor-patient-relationship, concern for
patients, loss of professional autonomy, difficulty with the consent procedure, lack of
rewards and recognition, and an insufficiently interesting question, while the patient
barriers included: additional demands of the trial, patient preferences, worry caused
by uncertainty, and concerns with information and consent. To overcome the barriers
to recruitment, the trial should address an important research question, data collection
should  be  as  simple  as  possible,  and  trials  should  be  carefully  planned  and  piloted
(Ross et al., 1999).
Possible reasons for non-compliance with screening for H. pylori reported were that
individuals invited were too busy (work commitments), they had family
commitments, the appointment time was inconvenient, the individuals were on
holiday or away from home, there was no recall of receiving an invitation letter, the
letter was not read or not fully understood, there were no symptoms, the individuals
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were not interested, they forgot about the appointment or had another illness/disability
(Stone MA et al., 1998a). Material deprivation and age was associated with a low
participation rate in screening so that the participation rate increased by age (Laine et
al., 2002).
4. Population screening and treating for H. pylori
Randomized controlled trials (RCT) generally provide more reliable information than
observational studies, and are widely accepted as the most powerful research method
for minimising bias when evaluating health technologies. A systematic review of
RCTs with good methodological quality and homogeneity, as well as an individual
randomized controlled trial with narrow confidence interval are regarded to offer the
best scientific evidence, which is not reached by non-controlled studies (Malfertheiner
et al., 2007). However, the participation rate in RCTs remains often low among other
reasons due to the possibility of receiving placebo (Ross et al., 1999; Lane et al.,
2002).
There are reports on population-based ‘screen-and-treat’ trials, in which study
population consists of randomly selected general population or subjects registered
with primary care centres. The trials can be classified to RCTs, controlled trials, and
other population trials.
4.1. Randomized controlled population trials
In a community screening programme for H. pylori in Leeds in 1994 a total of 32,929
randomly selected individuals aged 40-49 years and listed in 36 primary care centres
were invited to the study. Participants attended their local practice and their H. pylori
status was examined by UBT. Eradication was determined with a UBT six months
and two years after the first visit. A total of 8407 individuals participated in screening
and were evaluable (25.5% of those invited), 2329 tested positive (27.7% of those
evaluable), and 1161 individuals were randomized to H. pylori eradication therapy
including omeprazole (20mg), clarithromycin (250mg) and tinidazole (500mg) twice
daily for seven days, and 1163 individuals to identical placebo. H. pylori eradication
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rates were 73% per protocol and 61% in intention-to-treat analysis in the treatment-
group (Moayyedi et al., 2000a; Moayyedi et al., 2000b).
The Bristol Helicobacter project started in 1996 as a double-blind placebo-controlled
trial of the effect of H. pylori eradication on symptoms of dyspepsia. The target
population of 27,536 individuals aged 20-59 years and registered with seven primary
care centres in Bristol, UK and the surrounding areas was invited to undergo a UBT
(Lane  J  et  al.,  2002).  Eradication  was  determined  with  a  UBT  six  months  after
treatment. Of the participants, 23.5% had dyspepsia on study entry. A total of 10,537
individuals (38.3% of those invited) participated in screening, 1636 tested positive
(15.5% of those tested), and 1558 (95.2% of those tested positive) were randomized to
H. pylori eradication therapy including ranitidine-bismuth citrate (400mg) and
clarithromycin (500mg) twice daily for 14 days, or placebo (Lane et al., 2002). H.
pylori eradication rates were 91% per protocol and 84% in an intention-to-treat
analysis (Harvey et al., 2004).
4.2. Controlled population trials
In Odense, Denmark, a population-based intervention study was started to asses the
effect of H. pylori screening and eradication in general population on the prevalence
of dyspepsia, incidence of peptic ulcer disease and possible savings in health care
costs, and on the quality of life (Wildner-Cristiansen et al., 2003). The target
population of 80,643 individuals aged 40-64 years and living in Odense and the
surrounding municipalities was identified by their civil registration numbers in the
county’s population register, and 21,998 individuals were selected on the basis of
addresses and proportional to the number of persons in each 5-year age group in the
background population. The selected individuals were randomized by computer for an
intervention group, which was offered H. pylori screening and eradication, and a
control group by a one-to-one randomization. The screening was two-staged as a
positive in-office whole-blood-test-result was confirmed by UBT. The eradication
treatment included omeprazole (20mg), clarithromycin (500mg) and amoxicillin (1g)
twice daily for 7 days.
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H. pylori eradication was confirmed in 20% of the treated subjects by a second UBT
at least one month after eradication treatment. The prevalence of dyspepsia and the
quality of life were assessed using mailed questionnaires and information on the use
of endoscopies and the use of prescription medication was obtained from various
health registers. The participation rate was 63% and 1008 tested H. pylori positive
(17.5% of the 5749 participants). The H. pylori eradication was successful in 95% of
the tested subjects (Wildner-Christiansen et al., 2003).
4.3. Other community based trials
In Leichester, UK, a general population sample of  4015 subjects aged 21-55 years
was offered  a serological screening test for H. pylori though their general
practitioners (Stone et al., 1998b). H. pylori-positive subjects were offered a
prescription for eradication treatment and an information pack designed to encourage
good compliance. Success of treatment was assessed by UBT. The participation rate
in screening was 39%. Of the 235 (15%) subjects who were H. pylori-positive, 186
(79%) were treated. Eradication was confirmed in 170 (95%) of the 179 subjects who
had  a  UBT.  Assuming  a  15%  overall  prevalence  of H. pylori infection it was
estimated that H. pylori was eradicated in 29% of those infected in the target
population of 4015 subjects. Effectiveness of the programme was limited most
strongly by acceptance of the screening test (Stone et al., 1998b).
In Matsu Island in Taiwan, with a population of 8732 in 2003 according to Britannica
Online Encyclopaedia (http://www.britannica.com),  a  community-based  study  of H.
pylori therapy using the strategy of ‘test, treat, retest, and retreat initial treatment
failures’ was started in 2004 (Lee et al., 2006). The target population comprised of
3700 native residents of Matsu Island aged 30 years or older who were registered in
the  Island’s  population  list.  The  report  does  not  define  exactly  whether  the  study
population comprised of all or a part of the residents of the Island in the selected age-
group.
Residents of the Island have a high prevalence of H. pylori infection, and the annual
mortality rate for gastric cancer is 33 deaths per 100,000 population (Lee et al., 2006).
To ascertain the presence of pre-cancerous lesions and gastric cancer, the screening
was two-staged using UBT in the first stage and an endoscopy for those who tested
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positive in UBT in the second stage. Eradication success was confirmed by UBT.
Performing the study in collaboration with a community-based multiple screening
programme (Chen et al., 2004) and arranging the UBT-screening sites near shopping
centres resulted in a high participation rate of 71,8%. Of the 2658 participants
(including 1654 current and 1004 former residents of the Matsu Island), 1651 tested
positive in UBT (62.1% of the participants). Endoscopy was performed and an initial
eradication treatment including esomeprazole (40 mg) once daily, and amoxicillin
(1g) and clarithromycin (500mg) twice daily for seven days was received in 1132
individuals (68.6% of those tested positive). Of them, 939 (82.9%) returned for a
second UBT and the eradication rate was 86% per protocol and 71.4% in intention-to
treat-analysis. On the basis of the completed questionnaires of 886 valid reporters, the
eradication rates were 88.7% per protocol and 86.9% in intention-to-treat analysis. A
total of 105 individuals of those 131 demonstrating a treatment failure with the first
treatment were willing to receive retreatment including esomeprazole (40mg) and
levofloxacin (500mg) once daily, and amoxicillin (1g) twice daily for ten days. A
successful eradication was achieved in 91.4% of the 105 individuals retested with
UBT (Lee et al., 2006).
5. Public health perspective
The knowledge and management strategies concerning H. pylori infection among GPs
has been evaluated. The knowledge about H. pylori infection has not been effective at
primary care level, since in a worldwide survey, of the 470 randomly selected GPs
from 29 countries, 81%, 85% and 61% knew the causal relationship of H. pylori with
gastric and duodenal ulcers and gastric cancer, respectively, and PPI-based triple
therapies were prescribed by 89% of the responders (Huang et al., 2003). H. pylori
was considered relevant to dyspepsia management among 63% of the GPs, and 66%
treated new dyspepsia empirically, 18% chose endoscopic diagnosis and 13% used a
‘test and treat’ approach (Huang et al., 2003). In a study from England, 44 GP-
participants accounting for a population of 262,647 participated and among that
population, 6037 (2.3%) of patients were on long-term acid suppressing treatment.
Among them, only 131 (10%) of 1306 patients who had peptic ulcer disease had been
prescribed eradication therapy (Wright et al., 2001).
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PRESENT STUDY
AIMS OF THE PRESENT STUDY
The age-adjusted H. pylori seroprevalence rate in the adult population decreased from
51% to 34% from 1973 to 1994 in Vammala, a semiurban community in South-West
Finland with a population of about 16,000, before the current use of antimicrobials in
the treatment of helicobacter gastritis. Almost all H. pylori infected individuals show
elevated levels of specific IgG antibodies, and in about two-thirds of subjects the
specific IgA antibodies are elevated. Presence of H. pylori IgA antibodies has been
associated with a CagA-positive infection, which in turn is associated with an
increased risk of severe complications of H. pylori infection.
The aims of the present work were
1. to accelerate the decline of H. pylori gastritis by starting a unique population-
based, voluntary ’screen-and-treat’ programme in primary health care practice.
2. to examine risk factors for H. pylori infection in a Finnish young adult
population by a questionnaire.
3. to determine the accuracy of H. pylori IgG and IgA antibody tests for adults in
different  age-groups,  with  special  emphasis  on  the  presence  of  atrophic
gastritis.
4. to study whether an increase in the number of IgA-antibody-positive H. pylori
patients with age is a cohort phenomenon only, or  whether initially IgG-
antibody-positive H. pylori patients later develop an IgA response, and how
the elevated IgA antibody levels change during infection.
5. to determine whether the proportion of subjects infected with CagA+ or CagA-




We started a unique population-based, voluntary ’screen-and-treat’ programme in
primary health care (Study I), first as a pilot study in 1994 and since 1996 extending
the programme to include all over 6000 inhabitants in Vammala aged 15 to 40 years
and 45 years.
A total of 864 subjects were included in the pilot study (Study 1). Of these, 284
persons had participated in a health study in 1973 and they had been reinvited in 1994
to local health centre for venepuncture for H. pylori antibody testing (see below).
Blood samples were obtained from 275 subjects (97% of those 284 invited), including
162 (58.9%) females. The 1973 health study had been organized by the Social
Insurance Institution of Finland, which had carried out a population-based health
examination including collection and storage of blood samples in 1973. At that time, a
random  sample  of  adult  population  had  been  selected  from  the  National  Population
Register by computer. A total of 600 subjects had been invited by mail and 492 had
participated. The participation rate had been 84% in 15 to 74-year-old subjects in
1973.  From the sera which had been collected in 1973 and stored at -20C°, 408 sera
from 213 female and 195 male had been available in 1994, when a follow-up study on
the seroprevalence of H. pylori infection (Kosunen et al., 1997) had been started
(Group A). Of the subjects who had participated in the health study in 1973, 372 were
still alive in 1994.  Also they had been reinvited by mail to the local health centre for
venepuncture and 224 had given a new blood sample for H. pylori antibody testing.
Of the total of 864 subjects included in the pilot study, 580 persons were included
from a  random sample  of  600  residents  of  Vammala  selected  by  computer  from the
National Population Register in 1994. The random sample of 600 inhabitants had
included 50 females and 50 males from each 10-year age group between 15 and 74
years. Of the selected 600 subjects, 594 had been invited by mail to the local health
centre for venepuncture for H. pylori antibody testing, when the follow-up study on
the seroprevalence of H. pylori infection had been started (Kosunen et al., 1997).
Blood samples were obtained from 504 subjects (84% of the invited) including 262
females and 242 males (Group B). Of the 1994 random sample of 600 inhabitants, 14
individuals had participated in the 1973 health study and were included in the pilot
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Figure 1. Design of the pilot study in 1994 (Study I) and Studies III and IV. Register,
National Population Register.
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study in the above described group of 284 persons, and six subjects had been
excluded for other reasons. The study design is also presented in Figures 1 and 2.
Seroepidemiological findings on H. pylori infection and allergen specific IgE
concentrations, based partly on this material, have been published previously
(Kosunen et al., 2002).
In the ‘screen-and-treat’ programme (Study I), all individuals aged 15 to 40 years
living in Vammala according to the National Population Register received by mail in
1996 a questionnaire and an invitation to give a blood sample for H. pylori antibody
test. Subjects who had moved to Vammala after updating of the Register were
encouraged to participate in the study by announcements in local newspapers. The
filled questionnaires were collected at the same visit in Vammala Health Center as the
blood samples were taken. A total of 3092 (74%) of the 4174 subjects invited by mail
and further 234 subjects invited by newspapers gave a blood sample (Figure 2). Of the
3326 participants, 1758 (52.9%) were females.  In 1997-2000, the programme was
extended to reach each year all the 15 and 45-year-old inhabitants of Vammala, who
were invited by a letter to participate (Figure 2). A total of 717 teenagers including
369 (51.5%) females, (92.5% of those 775 invited), and a total of 584 adults including
318 (54.4%) females, (63% of those 927 invited), gave a blood sample.
In Study II, the data from 561 consecutive adult outpatients (age range, 16 to 91;
median age 56 years, 339 (60.4%) female), who had undergone gastroscopy due to
clinical indications at the primary care in Vammala Health Centre, Vammala, Finland,
from December 1998 to November 2002, was analysed. Patients who had been
successfully treated for helicobacter infection earlier were excluded.
Serum samples collected from participants belonging to the original Group A and
Group B in 1973 and 1994 and stored at -20C° were reanalysed in Studies III and IV
(Figure 1).
 In Study III, we reanalyzed data on paired sera stored at -20C° from a total of 560
subjects. The paired sera were obtained from 224 persons [initial age-range in 1973,
15-59 years; median age, 33 years; 131 (58.5%) females] ( (from the original Group
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A) who had taken part in the population based health survey in Vammala, Finland in
1973 and who had given a follow-up blood sample in 1994 in the follow-up study on
the seroprevalence of H. pylori infection (Series B), and from 336 persons [initial age-
range 30 to 58; median age 44 years, 207 (61.6%) females] who had participated both
in another health survey (Mini-Finland Health Survey, see below) during 1978-1980
and in a follow-up study on asthma and atopic diseases during 1997-1998 (SeriesA).
The Social Insurance Institution of Finland performed a comprehensive population-
based health survey (Mini-Finland Health Survey) during 1978-1980 in Finland
following pilot studies carried out in 1977 (Aromaa et al., 1989). A sample of 8000
subjects, representing all Finns aged 30 or over, was studied. The sampling method
was a two-stage stratified cluster design and the sample was self-weighting. A total of
7217 people (90% of the sample) participated in a basic health examination including
collection of a blood sample. A total of 403 adults, who initially took part in the Mini-
Finland Health Survey, participated in a follow-up study on asthma and atopic
diseases two decades (range 17.7 to 20.1 years, mean 19.0 years) later during 1997-
1998 (Karjalainen et al., 2002). Of these 403 adults, 139 persons either had asthma in
the original survey or had developed asthma during the follow-up period, whereas 264
persons not suffering from asthma or chronic obstructive pulmonary disease served as
controls.  Cases and controls were matched for age, gender and area of residence. Of
the 403 adults, paired serum samples, stored at -20°C, from 336 persons [initial age-
range 30 to 58; median age 44 years, 207 (61.6%) females], were available for the
present Study III.
In Study IV, we analysed the frozen sera collected from altogether 911 subjects in
Vammala in 1973 (n=408, from the original Group A) and in 1994 (n=503, from the
original Group B). Paired serum samples were available from 221 individuals of those










































































































































































































































































































































































































































































































































































































































The Ethics Committee of the Hospital District of Pirkanmaa approved the study and
the participants gave their written informed consent.  The studies were conducted
according to the Declaration of Helsinki. Most of the frozen sera utilized in Studies III
and IV had been collected before present legislation which provides a written consent
from the study subjects. Public Health Institute-wide legislation authorized the
examination of frozen sera obtained from former population-based health studies or




Serum samples were stored at -20C° until analysed. The paired sera were analysed in
parallel.  Antibodies to H. pylori were measured separately for IgG and IgA classes by
an in-house EIA, as described earlier and demonstrated (with cut-off titres of 700 for
IgG and 70 for IgA) a sensitivity and a specificity of 94% and 93% for IgG, and 73%
and 95% for IgA, respectively, in detecting H. pylori infection as compared to
histology and culture (Kosunen et al., 1997). H. pylori antibodies were also measured
by commercially available EIAs  Pyloriset EIA-G and Pyloriset EIA-A (Orion
Diagnostica, Espoo, Finland) with a sensitivity and a specificity of 99% and 94% for
the  IgG  test  and  95%  and  92%  for  the  IgA  test,  respectively,  with  cut-off  titres  of
>300 for IgG and > 250 for IgA (Oksanen et al., 1998). In 2000 the manufacturer
replaced the commercial test with new versions of the test, Pyloriset EIA-GIII and
Pyloriset EIA-AIII (Orion Diagnostica, Espoo, Finland). Local validation of the new
versions of the test resulted in a sensitivity and a specificity of 100% and 99% for the
IgG test and 52% and 97% for the IgA test, respectively, when used in the 15 to 49-
51
year-old subjects (Study II) and when values of 30 or higher were considered positive
instead of the cut-off value of 20 recommended by the manufacturer.
The in-house EIA alone was used in the pilot study as part of Study I, in Study III in
Series B, and in Study IV. Pyloriset EIA-III alone was used in Study III in Series A.
Both the in-house EIA and Pyloriset EIA were used in Study I in the population-based
‘screen-and-treat’ programme. The former version of the Pyloriset EIA was in use in
Study I until we started to use the new version of the test in 2000. In Study II, serum
samples were analysed by using both in-house EIAs and Pyloriset EIA-III test kits,
but only the results of Pyloriset EIAs were published.
Pepsinogen I
The  sera  were  stored  at  -20C°  until  analysed.  The  serum  PGI  concentration  was
measured  with  an  immunoenzymometric  commercial  assay  (Gastroset  PG1,  Orion
Diagnostica, Espoo, Finland). According to manufacturer’s instructions, PG1 values
below 28 microg/liter were considered low. With this limit, the sensitivity and
specificity for Gastroset PG1 were 81% and 99%, respectively (Oksanen et al., 2001).
PGI concentrations were measured in Studies I and II, but PGI results were reported
only in Study II.
CagA antibodies
The  sera  were  stored  at  -20C°  until  analysed.   Antibodies  to  the H. pylori CagA
antigen were determined using a recombinant CagA fragment by EIA. An optical
density ratio (ODR) of > 0.35 was considered positive. The sensitivity and specificity
of the test were 94.4% and 92.5%, respectively, in a US population (Blaser et al.,
1995). The assays were performed at least in duplicate. CagA antibodies were assayed
in Study IV.
Gastroscopy and biopsies
Gastroscopies (Study II) were performed in a routine manner by A.S-R. with two
biopsies from the gastric antrum, two biopsies from the gastric corpus for histologic
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examination. Additional biopsies, one from the antrum and one from the corpus, were
obtained for culture.  The evident macroscopical pathology was recorded.
H. pylori culture
The gastric biopsies (Study II) were mailed for culture in Transpocult-tubes (Orion
Diagnostica, Espoo, Finland). The minced specimens were inoculated for H. pylori
for up to 12 days on Brucella agar plates (Becton, Dickinson, Sparks, MD, USA)
supplemented with whole horse blood (7%) and on selective Brucella agar plates
containing Iso-Vitalex (1%), vancomycin (6mg/L), amphotericin B (2mg/L) and
nalidixid acid (20mg/L). The plates were incubated for up to 12 days in spec.
atmosphere at 37Cº. H. pylori was identified by colony appearance, Gram staining,
and positive reactions for oxidase, urease, and catalase.
Histology
Formalin fixed-biopsy specimens (Study II) were embedded in paraffin and tissue
sections were cut at three levels per biopsy and placed on one slide. The sections were
stained with haematoxylin and eosin, Alcian blue (pH 2.5) / PAS stain, and modified
Giemsa stain. Gastritis was classified according to the Sydney System (Price, 1991)
in a blinded arrangement by one pathologist (J.M.).
Urea breath test
UBTs (Study I) were performed after an overnight or at least four hours fast. An
aqueous solution of 150 ml water containing 75 mg citric acid solution was given first
and a breath sample was collected 5 min after ingestion, and an additional 50 ml of
water containing 13C-labelled urea was given. A new breath sample was obtained 30
min after the second ingestion. The samples were sent by mail to a private laboratory
(Keskuskadun laboratorio, Helsinki, Finland) for analysis by gas chromatography.
The cut-off values were determined as delta over baseline (DOB) >4 ‰ positive,
<2‰ negative, and 2-4‰ uncertain. Subjects were advised not to take acid
suppressive medication in the preceding 7 days and antimicrobials in the preceding
month before the UBT.
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Diagnosis of H. pylori infection
In Study I in the pilot study, the diagnosis of H. pylori infection was based on the IgG
antibody result (in-house EIA), and in the case of a negative IgG result on the positive
IgA antibody result. In the population-based ’screen-and-treat’ programme (Study I),
all  sera  were  tested  with  both  in-house  EIA and  Pyloriset  EIAs  and  diagnosis  of H.
pylori infection was based on a positive IgG antibody result in most of the subjects. In
the case of discrepancy between the IgG test results, the H. pylori positivity was based
on that IgG test demonstrating a result above the cut-off value. In the case of negative
results in both the IgG tests, the subjects were regarded as H. pylori positive if the in-
house IgA antibody test was positive.
In Study III, persisting H. pylori infection was defined as a positive IgG antibody
result at the beginning and at the end of the follow-up period. When evaluating the
changes in IgA and IgG antibody levels and antibody status, the positivity was based
on antibody level exceeding the cut-off value for the test evaluated. Seroconversion
and seroreversion was defined on the basis of IgG antibody result.
In Study IV, the H. pylori-positivity  was  defined  as  a  positive  result  in  any  of  the
three serological assays used (in-house IgG, in-house IgA and CagA). H. pylori-
negative  status  was  defined  when  all  three  assays  were  negative.   In  those  subjects
with paired sera from 1973 and 1994, seroconvesion and seroreversion were defined
on the basis of IgG response to the acid glycine extracted H. pylori antigen (in-house
IgG).
Patients in Study II were considered H. pylori positive if culture or histology were
positive and H. pylori negative if both culture and histology were negative.
UBT was used in border-line antibody result cases at baseline to confirm the
diagnosis of H. pylori infection (Study I).
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Eradication therapy
All H. pylori antibody-positive subjects were offered antimicrobial therapy in the pilot
study in 1995 and in the population-based ‘screen-and-treat’ programme started in
1996 (Study I) as a part of a general practice consultation by A. S-R., and all treated
subjects were invited by mail to a new general practice consultation and a serologic
follow-up six months later.
In the pilot study, the first-line therapy included amoxicillin (500mg) q.i.d.,
metronidazole (400mg) t.i.d. and lanzoprazole (30mg) b.i.d. for 14 days, and the
second-line therapy (for those allergic to amoxicillin and for those with a treatment
failure in triple therapy) consisted of tetracycline (500mg) q.i.d., metronidazole
(400mg) t.i.d., and bismuth subcitrate (240mg) and lanzoprazole (30mg) b.i.d. for 14
days.
In the population-based study, the only exclusion criterion was alcoholism due to the
possibility  of  an  antabus  effect  of  metronidazole.  In  the  case  of  pregnancy,  the
eradication therapy was offered after lactation. The first-line therapy included
amoxicillin (1000mg) b.i.d., metronidazole (400mg) t.i.d. and lanzoprazole (30mg)
b.i.d. for 7 days. Subjects allergic to amoxicillin were given tetracycline (500mg)
q.i.d., metronidazole (400mg) t.i.d., bismuth subcitrate (240mg) and lanzoprazole
(30mg) b.i.d. for 7 days. After treatment failure the second-line treatment was
amoxicillin (1000mg), clarithromycin (500mg) and lanzoprazole (30mg) b.i.d. for 7
days, or metronidazole (400mg) t.i.d., and clarithromycin (500mg) and lanzoprazole
(30mg) b.i.d. for 7 days for those allergic to amoxicillin. The patients could purchase
the medicines from local pharmacies for a reduced price, due to support from
pharmaceutical companies.
Criterion for cure
Pre- and post-treatment sera (Study I) were always tested in the same run to determine
the decline of antibody levels. The criterion for successful eradication therapy was a
decline of at least 40% in the IgG antibody level in six months.
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UBT (Study I) was used in border-line cases at follow-up, and to confirm eradication
failures before retreatment in the population-based ‘screen-and-treat’ programme.
Questionnaire
A printed questionnaire (Study I) was used in 1996 to obtain statistically useful or
personal information from individuals. The 65 questions formulated for this study
covered the background of the participant, information on childhood household,
smoking habits, consumption of alcohol, use of acetylsalicylic acid (ASA) and
NSAIDs in the previous six months, diagnosed H. pylori-associated diseases,
gastrointestinal symptoms evaluated by frequency and intensity (5-graded scale) and
doctor consultations, medical examinations, medications and sick leave due to upper
abdominal symptoms in the previous six months. Quality of life and situation in life
were also documented.
Statistical analysis
The statistical significance of the differences between H. pylori antibody-positive and
antibody-negative subjects in Study I was tested first using Pearson’s chi-square,
Mann-Whitney’s U, and Fisher’s exact tests, and the confounding factors were
controlled by Mantel-Haenszel’s test and by multivariate regression analysis. Each
risk factor remaining statistically significant was analysed separately in a univariate
model, and those factors remaining statistically significant were further analysed
using a multivariate logistic regression model. The results were expressed as odds
ratios (OR), 95% confidence intervals (CI) and p-values. Two-sided p-values less than
0.05 were considered statistically significant.
The sensitivity, specificity, positive and negative predictive values were determined
for each EIA test and compared with the prevalence of H. pylori as based on histology
or culture or both in Study II. The statistical significance of the improvement of the
specificity figures was evaluated using Pearson’s Chi-Square and Fisher’s Exact tests,
and a trend in proportion by age was examined using a linear by linear test.
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The statistical significance of the increase in IgA titres in Study III was evaluated by
using  Wilcoxon’s  signed  rank  pair  test,  and  the  increase  in  the  number  of  IgA
responders was examined by using McNemar’s test. Differences in frequencies of
response to Cag antigen among groups in Study IV was studied by Pearson’s chi-
square test, and the magnitude of the responses in different groups was examined
using the Student’s t test for independent samples.
The statistical analysis were done by using SPSS 12.0 software packages (SPSS  Inc,
Chicago, IL, USA).  In Study II, StatXact 5.0 (Cytel Inc, MA, USA) was also used.
RESULTS
The ‘screen-and-treat’ study (Study I)
Participation rates
The participation rates in the ‘screen-and-treat’ programme in Vammala, Finland are
summarised in Table 1 (Study I).  A total of 3316 (99.7%) of the 3326 participants of
the population-based programme (Study I) returned the questionnaire, including all of
the 406 antibody-positive subjects and 2910 (99.7%) of the 2920 antibody-negative
subjects.
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Table 1.  Participation rates in different phases of the 'screen-and-treat' programme in
Vammala, Finland.  NPR, National Population Register.
Invited Participated  Female
YEAR, source AGE N N % N %
1994, pilot study 15-75 864 765 88.5 411 53.7
1996, from NPR 15-40 4174 3092 74.1
1996, newspaper invitation 15-40 234
1996, total 15-40 3326 1758 52.9
1997-2000, from NPR 15 774 716 92.4 369 51.5
1997-2000, from NPR 45 927 584 63.0 318 54.4
Risk factors for non-compliance
We evaluated the reasons for non-compliance by analysing the questionnaire results.
Of the 406 antibody-positive participants, 46 (11.3%) did not show up to receive
eradication therapy. Current smoking was the only characteristic associated with the
not appearing at the consultation, as 64% of those not showing up and 34% of those
consulting the general practitioner to receive eradication therapy were current
smokers (p < 0.0001, OR 3.3, 95% CI 1.7 to 6.4). Among those consulting the general
practitioner, the parents’ education was found to be associated with the non-
compliance so that, a higher basic education of both mother and father was more
common  among  participants  who  were  drop-outs  than  among  those  who  completed
the follow-up (Table 2). In addition, current smoking and current alcohol
consumption were more common in those who had dropped out from the follow-up
(Table 2).
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Table 2. Odds ratios with 95% confidence intervals and prevalences of risk factors for
non-compliance in the follow-up after treatment. Results from univariate analyses*.
Information collected by a questionnaire filled out by the participant at the beginning
of the 'screen-and-treat' programme. Ref.categ, reference category.
Drop outs Responders 95% CI
n % n % P-value OR Lower Upper
Mother’s basic education 0,006
elementary school (ref.categ) 23 64,9 244 83,0
middle school or comprehensive school 8 21,6 42 14,3 0,002 6,35 1,93 20,96
upper secondary school 5 13,5 8 2,7 0,084 3,28 0,851 12,65
Father's basic education 0,037
elementary school (ref.categ) 28 73,7 253 87,5
middle school or comprehensive school 6 15,8 28 9,7 0,019 4,52 1,28 15,96
upper secondary school 4 10,5 8 2,8 0,265 2,33 0,526 10,35
Smoking
current smoking** 25 62,5 91 30,5 <0,0001 3,79 1,91 7,52
Alcohol consumption
current alcohol consumption** 36 90,0 222 74,7 0,041 3,04 1,05 8,85
former consumtion in those who have 10 90,9 42 42,9 0,015 13,3 1,64 111,1
stopped
*For binary logistic regression analyses, the variables measuring educational level
were entered as categorical variables, and other variables as dichotomical variables.
SPSS 12.0.1. software packages (SPSS, Inc., Chicago, Ill.) was used.
** The question was related to the last six months.
Prevalence rates of H. pylori infection
The seroprevalence rates increased by age (Study I) in 1994 from 4.6% to 69.4% in
15 to 75-year-old subjects (Table 3) and in 1996 from 4.2% to 22.2% in 15 to 40-
year-old individuals in the 5-year age groups (Table 4).  Each year in 1997-2000 all
15 and 45-year-old persons were invited to the programme and the seroprevalence
rate was 3.2% among the teenagers and 27.4% among the 45-year-old adults (Table
5).
The initial H. pylori seroprevalence rates were calculated to have decreased from 39%
to 19% in the pilot study, from 12% to 4% among subjects aged 15 to 40 years, from
3% to 2% among the 15-year-old subjects, and from 27% to 12% among the 45-year-
old subjects (Tables 3-5).
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Table 3. Seroprevalence rates in males, in females, and in both genders combined at
base-line in 1994, and calculated seroprevalence rates after the 'screen-and-treat'
programme in 5-year age-groups, in the pilot study in Vammala, Finland. AB+,
number of antibody-positive* subjects;  %calc, calculated seroprevalence rate.
M a l e F e m a l e A l l  participants After treatment
AGE AB+ % AB+ % ALL AB+ % AB+ %calc
15-20 0 0.00 2  8.00 44 2  4.55 1  2.27
21-25 2 14.29 1  5.26 33 3  9.09 1  3.03
26-30 1  7.14 4  19.05 35 5 14.29 1  2.86
31-35 2  8.33 3  13.04 47 5 10.64 2  4.26
36-40 8 21.62 12  27.27 81 20 24.69 6  7.41
41-45 11 29.73 21  41.18 88 32 36.36 15  17.05
46-50 13 30.23 21  42.86 92 34 36.96 18  19.57
51-55 16 48.48 19  44.19 76 35 46.05 16  21.05
56-60 22 55.00 22  55.00 80 44 55.00 22  27.50
61-65 23 62.16 16  53.33 67 39 58.21 14  20.90
66-70 16 64.00 21  60.00 60 37 61.67 21  35.00
71-75 25 80.65 18  58.06 62 43 69.35 31  50.50
total 139 39.27 160 38.93 765 299 39.08 148  19.35
* In-house IgG and IgA antbody results combined.
Table 4. Seroprevalence rates in males, and in females, and in both genders combined
at base-line in 1996, and calculated seroprevalence rates after the intervention in 5-
year age-groups in the 'screen-and-treat' programme in Vammala, Finland. AB+,
number of antibody-positive* subjects; %calc, calculated seroprevalence rate.
M a l e F e m a l e A l l  participants After treatment
AGE AB+ % AB+ % ALL AB+ % AB+ %calc
15-20 21  4.44 18  4.01 922 39  4.23 14  1.52
21-25 17  8.99 24  8.57 469 41  8.74 8  1.71
26-30 26 10.24 35 11.36 562 61 10.85 23  4.09
31-35 56 17.45 57 15.49 689 113 16.40 35  5.08
36-40 79 23.87 73 20.68 684 152 22.22 41  5.99
total 199  12.69 207 11.77 3326 406 12.21 121  3.64
* IgG and IgA antbody results combined, assayed by using in-house and
Pyloriset EIAs.
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Table 5. Seroprevalence rates in both genders separately and combined at base-line in
1997-2000, and calculated seroprevalence rates after the programme in 15 and 45-
year-old participants in the ‘screen-and-treat’ programme in Vammala, Finland. AB+,
number of antibody-positive* subjects; %calc, calculated seroprevalence rates; yr,
year.
M a l e F e m a l e A l l  participants After treatment
AGE YEAR AB+ % AB+ % ALL AB+ % AB+ % calc
15 yr 1997 3 3.33 2 2.00 190 5 2.63 1  0.53
1998 2 2.22 3 2.91 193 5 2.59 4  2.07
1999 3 3.30 3 3.49 177 6 3.39 5  2.82
2000 1 1.32 6 7.50 156 7 4.49 5  3.21
97-00 9 2.59 14 3.79 716 23 3.21 15  2.09
45 yr 1997 24 31.17 27 30.68 165 51 30.91 18  10.91
1998 22 28.20 24 26.67 168 46 27.38 18  10.71
1999 14 24.14 17 24.29 128 31 24.22 16  12.50
2000 14 26.41 18 25.71 123 32 26.02 19  15.45
97-00 74 27.82 86 27.04 584 160 27.40 71  12.16
* IgG and IgA antbody results combined, assayed by using in-house and
  Pyloriset EIAs.
Eradication rates
All H. pylori-antibody-positive individuals were offered antimicrobial therapy (Study
I). In the pilot study 157 (52.5%) of those infected were treated and the eradication
rate was 89.8%. The eradication rates after first treatment were 82.2% and 77.6% per-
protocol and 71.9% and 62.9% in intention-to-treat in subjects invited to the ‘screen-
and-treat’ programme in 1996 and 1997-2000, respectively. After the second
treatment, the per-protocol eradication rates were 83% and 83%, and the-intention-to-
treat eradication rates were 66% and 62% in subjects invited to the programme in
1996 and in 45-year-old subjects invited in 1997-2000, respectively. The two
teenagers who were treatment failures in 1997-2000 refused a second course of
treatment.
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Table 6. Grade and location of gastric atrophy in H. pylori-positive* and -negative**
subjects and prevalence of low Pepsinogen I values in patients with corpus atrophy.
Number of patients with the indicated results. PGI, pepsinogen I.
Grade of H. pylori  + H. pylori  -
atrophy a PGI <28b / corpus atrophy antrum atrophy PGI <28 / corpus atrophy antrum atrophy
(prevalence) (prevalence)
0  1 / 130 154  10 / 328 366
1  1 / 31     (3.4%) 17    4 / 13    (31%) 7
2  4 / 14     (29%) 5  10 / 16    (62%) 3
3  1 / 4       (25%) 2  21 / 22    (95%) 0
unknown c  0 / 2 3    0 / 1 4
total  7 / 181 181  41 / 380 380
* H. pylori+, H. pylori positivity was based on positive histology or culture or both.
** H. pylori -, both histology and culture were negative.
a Grade of corpus/antrum atrophy according to the Sydney System
b Pepsinogen I (Gastroset PGI, Orion Diagnostica, Espoo, Finland), low value
 <28microg/liter.
c There were 3 patients with antrectomy and 4 patients with superficial biopsy
  specimens without glands.
Accuracy of H. pylori antibody assays (Study II), with special emphasis on
atrophic gastritis
Presence of H. pylori and atrophic gastritis on gastric mucosa, and endoscopic findings
Of the 181 H. pylori-positive patients, culture was positive in 173 (95.6%), and
microscopy of the histological preparations was positive in 161 (88.9%) (p = 0.0305).
Atrophic gastritis was detected in histology in 66 (36.5%) of the 181 patients with H.
pylori gastritis, and in 54 (14.2%) of the 380 H. pylori-negative patients (p < 0.0001).
The grade and location of gastric atrophy among H. pylori-positive and -negative
subjects, and the prevalence of low PGI values in patients with corpus atrophy is
shown in Table 6. Atrophic gastritis based on histology or a low PGI
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Table 7.  Characteristics of the patients with a false positive antibody result in any of
the four tests (combination of IgG and IgA results) but H. pylori-negative results in
culture and histology.  N, normal gastric mucosa in histology; G, chronic gastritis
without helicobacters in biopsy specimens;  CA, gastric malignancy.
Age-group Number (%) N u m b e r   o f   h i s t o l o g i c a l   f i n d i n g s
(n) of false grade of corpus-atrophya grade of antrum-atrophya CA
positives N G (PGI < 28 microg/liter b)
0 1 2 3 0 1 2 3
15-49 (157) 6   (3.8%) 5 1  6 (0) -  -  - 0  -  -  - 0
50-64 (192) 17   (8.8%) 9 8 11 (0) - 2 (0) 4 (0) 17  -  -  - 0
> 65  (212) 43 (20.3%) 4 39 23 (3) 8 (3) 7 (5)  4 (4)c 35 6  1d  -  3e
a Grade of corpus/antrum atrophy according to the Sydney System (range 0-3).
b Pepsinogen I (Gastroset PGI, Orion Diagnostica, Espoo, Finland).
c 1 patient with superficial biopsy specimen without glands, explaining missing data
   in corpus  atrophy numbers.
d 1 patient with antrectomy, explaining  missing data in antrum atrophy numbers.
e 2 adenocarcinomas and 1 lymphoma.
value was more common  in the older age groups, appearing in 10.2%, 17.2%, and
39.6% of the patients aged 15-49, 50-64, and >65 years, respectively ( p = 0.0001).
Characteristics of the patients with a false positive antibody result but H. pylori-
negative results in culture and histology, related to gastric atrophy, are presented in
Table 7.   Peptic ulcer disease was detected in 22 (12.1%) infected patients and in five
(1.2%) H. pylori-negative patients ( p < 0.0001).
Accuracy of H. pylori antibody assays
The accuracy of H. pylori antibody assays was evaluated in the age-groups of 15-49,
50-64, and >65  years.  The  sensitivities,  specificities,  PPVs,  and  NPVs  of  both
Pyloriset and in-house assays are shown in Table 8, although only the results of
Pyloriset EIA were published in article (Study II).  The sensitivities of the both IgG
tests were high in all age-groups, but the specificities for the in-house and Pyloriset
IgG tests declined by age-group from 99.3 and 98.5% for those aged 15 to 49 years to
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Table 8.  Sensitivities,  specificities,  PPVs, and NPVs of H. pylori EIA antibody tests
for different age-groups for all patients and after exclusion of patients with atrophic
gastritis a. PPV, positive predictive value; NPV, negative predictive value.
Age-group (years) No.of Test Sensitivity Specificity PPV NPV p-value for
prevalence (%) b patients increase in
specificity
15 - 49 157
H. pylori + 13.4% Pyloriset EIA-GIII 100 (100) 99.3 (99.3) 95.4 (95.4) 100 (100)
Histology+ 12.1% In-house IgG 100 (100) 98.5 (98.5) 91.3 (91.3) 100 (100)
Culture+ 13.4%
Pyloriset EIA-AIII 52.4 (52.4) 97.1 (97.1) 73.3 (73.3) 92.9 (92.9)
In-house IgA 57.1 (57.1) 100 (100) 100 (100) 93.8 (93.8)
Pyloriset EIA-GIII + AIII c 100 (100) 96.3 (96.3) 80.8 (80.8) 100 (100)
In-house IgG + IgA 100 (100) 98.5 (98.5) 91.3 (91.3) 100 (100)
50 - 64 192
H. pylori + 37.5% Pyloriset EIA-GIII 98.6 (98.6) 94.2 (97.4) 91.0 (95.9) 99.1 (99.1)   ns d
Histology+ 33.3% In-house IgG 100 (100) 90.8 (94.8) 94.0 (92.3) 100 (100) ns
Culture+ 36.5%
Pyloriset EIA-AIII 80.6 (80.6) 91.7 (94.8) 85.3 (90.6) 88.7 (88.7) ns
In-house IgA 75.0 (75.0) 96.7 (98.3) 93.1 (96.4) 86.6 (86.6) ns
Pyloriset EIA-GIII + AIII 98.6 (98.6) 89.2 (93.0) 84.5 (89.9) 99.1 (99.1) ns
In-house IgG + IgA 100 (100) 90.0 (93.9) 85.7 (91.1) 100 (100) ns
> 65 212
H. pylori + 41.5% Pyloriset EIA-GIII 98.9 (98.9) 75.0 (93.0) 73.7 (92.5) 98.9 (98.9) <0.0001
Histology+ 36.8% In-house IgG 98.9 (98.9) 73.4 (88.3) 72.5 (87.9) 98.9 (98.9) 0.0049
Culture+ 38.7%
Pyloriset EIA-AIII 86.4 (86.4) 79.0 (92.4) 74.5 (90.5) 89.1 (89.1) 0.0043
 In-house IgA 68.2 (68.2) 82.3 (93.6) 73.2 (89.5) 78.5 (78.5) 0.009
Pyloriset EIA-GIII + AIII 100 (100) 70.2 (86.1) 70.4 (86.3) 100 (100) 0.0044
In-house IgG + IgA 100 (100) 72.6 (87.4) 72.1 (87.1) 100 (100) 0.0062
All 561
H. pylori + 32.3% Pyloriset EIA-GIII 98.9 (98.9) 89.7 (96.9) 82.1 (82.1) 99.4 (99.4) <0.0001
Histology+ 28.7% In-house IgG 99.4 (99.4) 87.9 (94.3) 79.6 (90.0) 99.7 (99.7) 0.0023
Culture+ 30.8%
Pyloriset EIA-AIII 80.1 (80.1) 89.5 (95.0) 78.4 (88.9) 90.4 (90.4) 0.0055
In-house IgA 69.6 (69.6) 93.2 (97.5) 82.9 (93.3) 86.5 (86.5) 0.005
Pyloriset EIA-GIII + AIII 99.4 85.5(nc) e 76.6 (nc) 99.7 (nc) nc
In-house IgG + IgA 100 87.4 (nc) 79.0 (nc) 100 (nc) nc
a Atrophic gastritis was verified by histology or a Pepsinogen I value of less than 28
   microg/liter. Results after exclusion of those patients with atrophic gastritis and a
   false positive antibody result are shown in parentheses.
b H. pylori+, prevalence of H. pylori as based on histology or culture or both;
  Histology+, prevalence of H. pylori as based on histology alone;
  Culture+, prevalence of H. pylori as based on culture alone.
c Combination of IgG and IgA results.
d Non significant.
e Not calculated because of different numbers of false positive subjects in IgG and
IgA tests.
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75.0 and 73.4% for those aged > 65 years, respectively.  The sensitivities of the both
IgA tests were low in the youngest age-group, but increased by age-group.
The exclusion of false positive results for patients with atrophic gastritis as based on
histology or a PGI value < 28microg/liter improved the specificities for the in-house
and Pyloriset IgG tests to 97% and to 93%, and to 95% and to 94%, in patients aged
50 to 64 years and 65 years or more, respectively.
Changes in H. pylori antibody levels (Study III)
In series A in Study III, seven (2.1% of all 336 subjects) originally antibody negative
subjects in the Mini-Finland Study had during the two decades’ follow-up developed
a positive IgG response and five of them had also become positive for IgA antibodies.
The calculated annual rate of new infections was 0.1%. The number of IgG
seroreverters was 35 (10.4% of 336) resulting in a calculated annual rate of 0.5% for
seroreversions. Of these, there was a change in IgA status from positive to negative in
15 subjects, whilst in 9 subjects, despite negative IgG serology, there was persisting
IgA positivity at follow up.
Within the follow-up period of two decades among the 268 subjects (from both Series
A and Series B) with a persisting positive IgG response, there was an increase in the
number of IgA seroconverters, which did not reach statistical significance (Table 9).
In the 197 subjects with a persisting positive IgA and IgG response during the follow-
up period, the median IgA titres increased  by 48% (p < 0.0001) and 22% (p =
0.0241) in Series A and B, respectively (Table 10). The changes in the median IgG
titres (-1% and -18% in Series A and Series B, respectively) were not significant.
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Table 9.  IgA antibody status during H. pylori infection in 268 subjects with a
persisting positive IgG response.
Initial Follow-up Number Proportion p-value
(%) for change
Negative Negative 39  14.5
Positive Positive 197  73.5
Negative Positive 21    7.8 0.1102*
Positive Negative 11    4.1
* The increase in the number of IgA responders was evaluated
   using  McNemar's test.
Table 10. Long-term changes in median IgG and IgA titres during H. pylori infection
in 197 subjects with a persisting positive IgG and IgA response.
Vammala study Mini-Finland study
n = 57 n = 140
Median Median Median Median
IgG titre IgA titre IgG titre IgA titre
Initial 5500 180 2940 885
Follow-up 4500 220 2910 1310
Change of medians (%)  - 18.2%  + 22.2%  - 1.0%  + 48.0%
p-value for change* 0.5000 0.0241 0.0932 < 0.0001
EIA-test used in-house IgG in-house IgA Pyloriset EIA-GIII Pyloriset EIA-AIII
* Statistical significance for the change in medians was examined with Wilcoxon's
signed rank pair test.
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Table 11. Change in seroprevalence (%) of H. pylori antibodies against acid glycine
extract (in-house EIA) and CagA antigen between 1973 and 1994 by age. H.pylori+,
positive H. pylori antibodies of classes IgG and IgA or both; CagA+, positive CagA
antibodies; ns, non significant. 1973 n= 408, 1994 n=503.
H. pylori+ CagA+ H-pylori + CagA -
Age 1973 1994 P-value 1973 1994 P-value
14-44 years  34.3 8.0 <0.0001  11.6  5.9 0.03
> 45 years  40.7 31.6 ns  30.7  24.1 ns
CagA-antibodies (Study IV)
Validation of CagA threshold in the tested population
As gastric biopsies were not obtained from the subjects in Study IV, we used sera
from 65 subjects who were positive both in 1973 and in 1994 for both IgG and CagA
antibodies as a gold standard to define subjects being persistently infected with CagA-
positive H. pylori strains. For these 130 sera, the mean (SD) ODR in the CagA assay
was 0.78 (0.22). By subtracting two SD-intervals from the mean ODR, we defined a
level that was 97.5% likely to represent truly positive CagA status. This value (0.34)
was almost identical to the prior cut-off value of 0.35 determined previously (Blaser
et al., 1995).
Changes in the seroprevalence rate of CagA antibodies
The seroprevalence of CagA antibodies declined from 36.5% in 1973 to 20.4% in
1994 in Vammala.  The decline was largest among younger subjects aged 14 to 44
years (Table 11). We found 14 (3.4%) subjects in 1973 and 20 (3.9%) subjects in
1994, who were CagA antibody-positive but demonstrated negative result for in-
house IgG and IgA antibodies.
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Table 12. Stablity of antibody responses to H. pylori antigens in 21 years follow-up
in 95 subjects who were H. pylori IgG antibody-positive in 1973.
Number of subjects positive
with indicated assay Antibody level
Assay 1973 1994 % 1973 1994
H. pylori  IgG* 95 87 91.6 3179 3009
H. pylori  IgA* 59 54 91.5 180 201
CagA IgG** 69 69 100 0.75 (0.24) 0.80 (0.21)
*  In-house IgG or IgA, shown as resiprocal geometric mean titers (RGMT)
** CagA IgG, shown as mean optical density ratio (ODR) units (SD)
Changes in overall H. pylori positivity and CagA antibody status
Paired sera from 221 subjects obtained both in 1973 and 1994, were examined to
study whether H. pylori or CagA serostatus had changed. In total, only 12 (5.4%)
subjects had a change in overall H. pylori status during the two decades follow-up
period. In nine subjects (7.8% of the subjects who were seronegative in 1973), the
overall status changed from negative to positive (giving a crude seroconversion rate of
0.4% per year), and eight of the nine also became positive in the CagA assay.  In three
subjects (2.8% of the 106 subjects who were seropositive in 1973), the overall status
changed from positive to negative (the crude seroreversion rate was 0.13% per year),
and all the three had been CagA antibody-negative in 1973 and remained negative in
1994.
Changes in the levels of CagA antibodies
The paired sera from 221 subjects obtained both in 1973 and 1994, were also
examined to determine the degree of fluctuation in the level of antibodies present
among H. pylori-positive subjects in the two decades follow-up period. In Table 12 is
shown the stability of antibody responses to H. pylori antigens (measured by the in-
house EIAs for IgG and IgA antibodies, and the EIA for CagA IgG antibodies).
Among those who were CagA-positive in 1973 and 1994, the calculated mean annual
increase in antibody level was 0.3%.
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Risk factors for H. pylori infection (Study I)
The printed questionnaire including 65 questions was used to obtain statistically
useful data on possible risk factors for H. pylori infection from individuals who
participated in the ‘screen-and-treat’ study. The questionnaire was returned by 99.7%
of the participants in 1996. Statistically significant risk factors for H. pylori infection
and characteristics of H. pylori-positive subjects compared to H. pylori-negative ones
are shown in Table 13.
Low education
Parents’ education was associated with H. pylori infection  so  that,  in  the  case  of  a
mother both low basic and low vocational education and in the case of a father low
basic education reached statistical significance. Participant’s basic education was
associated with the infection, as well.
Childhood household
In childhood household, the crowding variables (number of family members, number
of persons sharing a bedroom, sharing the bed with some one else) and using well
water were associated with H. pylori infection (Table 13), but kissing habits between
the participant and the parents and the siblings were not associated with the infection.
Life style
Current smoking and current alcohol consumption were significantly more common
among H. pylori-infected than H. pylori-negative individuals as shown in Table 14. A
higher number of daily cigarettes was found to be associated with H. pylori infection,
(OR 1.88, 95% CI 1.30-2.71), as 39% (n = 57) and 25.4% (n = 204) of the antibody-
positive and -negative smokers, respectively, smoked more than 14 cigarettes daily (p
= 0.001). In addition, alcohol consumption was more severe in H. pylori-positive
subjects (Table 14).
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Table 13a. Odds ratios with 95% confidence intervals and prevalences of risk factors
in H pylori-positive and -negative subjects aged 15 to 40 years. Results from
univariate analyses*.  Information collected by an epidemiologic questionnaire filled
out by the participant at the beginning of the 'screen-and-treat' programme in
Vammala, Finland. Ref.category, reference category.
H pylori  positive H pylori  negative Results from univariate analyses
n % n % P-value OR 95% CI
Mother’s basic education <0.0001
elementary school 299  80.6 1690  62.8 <0.0001  4.04  2.29 - 7.14
middle school or comprehensive school 59  15.9 705  26.2 0.039  1.91  1.03 - 3.54
upper secondary school (ref.categ) 13  3.5 297 11.0
Father's basic education <0.0001
elementary school 316  85.9 1954  73.5 0.002  2.46  1.39 - 4.37
middle school or comprehensive school 39  10.6 505  19.0 0.624  1.18  0.61 - 2.25
upper secondary school (ref.categ) 13  3.5 198  7.5
Mother's vocational education <0.0001
no vocational training 181  51.1 927  35.5 0.002  3.51  1.61 - 7.65
vocational courses 79  22.3 577  22.1 0.026  2.46  1.11 - 5.47
vocational school 63  17.8 586  22.5 0.108  1.93  0.87 - 4.32
college level degree 24  6.8 394  15.1 0.835  1.1  0.46 - 2.61
academic degree (ref.categ) 7  2.0 126  4.8
Participant's basic education <0.0001
elementary school 42  11.0 137  5.1 <0.0001  2.86  1.90 - 4.31
middle school or comprehensive school 252  66.0 1740  64.5 0.021  1.35  1.04 - 1.75
upper secondary school (ref.categ) 88  23.0 821  30.4
Childhood home
having well water 259  68.2 1531  55.8 <0.0001  1.69  1.35 - 2.13
sharing bed with someone 112  29.5 489  17.9 <0.0001  1.92  1.51 - 2.44
no. of family members <0.0001  1.15  1.09 - 1.21
no. of persons in bedroom <0.0001  1.3  1.20 - 1.41
Smoking
current smoking** 144  37.7 738  26.8 <0.0001  1.65  1.32 - 2.06
Alcohol consumption
current alcohol consumption** 292  76.8 1755  63.8 <0.0001  1.88  1.47 - 2.42
Anfavourable situation1 of life related to…
economical situation1 360 95.5 2380 87.7 <0.0001  2.97  1.80 - 4.90
housing conditions1 270  71.2 1627  59.6 <0.0001  1.68  1.33 - 2.13
overal situation1 307  81.0 1980  72.6 0.001  1.61  1.23 - 2.11
1very good or good / average, bad or very bad
Occurence of GORD-symptoms** 189  55.9 1002  42.0 <0.0001  1.75  1.39 - 2.20
Medical examinations and sick leaves because of dyspeptic symptoms
Gastroscopy 44  11.6 170  6.2 <0.0001  1.99  1.40 - 2.83
X-ray of ventricle 51  13.5 220  8.0 <0.0001  1.79  1.29 - 2.47
being on sick leave** 11  2.9 34  1.2 0.012  2.4  1.21 - 4.79
H. pylori  associated diseases
gastritis 28  7.3 76  2.8 <0.0001  2.79  1.79 - 4.37
peptic ulcer disease 16  4.2 22  0.8 <0.0001  5.45  2.83 - 10.47
*For binary logistic regression analyses, the variables measuring educational level were entered as
categorical variables, the crowding variables were entered as continuous variables and other variables
as dichotomical variables.  SPSS 12.0 software packages (SPSS, Inc.,Chicago, Ill.) was used.
** The question was related to the last six months.
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Table 13b. Odds ratios with 95% confidence intervals and prevalences of risk factors in
H. pylori-positive and -negative subjects aged 15 to 40 years. Results from multivariate
analysis*.  Information collected by an epidemiologic questionnaire filled out by the
participant at the beginning of the 'screen-and-treat' programme in Vammala, Finland.
Ref.category, reference category.
H pylori  positive H pylori  negative Results from multivariate analysis
n % n % P-value OR 95% CI
Mother’s basic education <0.0001
elementary school 299  80.6 1690  62.8 0.001  3.02  1.56 - 5.87
middle school or comprehensive school 59  15.9 705  26.2  0.131  1.73 0.849 - 3.51
upper secondary school (ref.categ) 13  3.5 297 11.0
Father's basic education ns
elementary school 316  85.9 1954  73.5
middle school or comprehensive school 39  10.6 505  19.0
upper secondary school (ref.categ) 13  3.5 198  7.5
Mother's vocational education ns
no vocational training 181  51.1 927  35.5
vocational courses 79  22.3 577  22.1
vocational school 63  17.8 586  22.5
college level degree 24  6.8 394  15.1
academic degree (ref.categ) 7  2.0 126  4.8
Participant's basic education ns
elementary school 42  11.0 137  5.1
middle school or comprehensive school 252  66.0 1740  64.5
upper secondary school (ref.categ) 88  23.0 821  30.4
Childhood home
having well water 259  68.2 1531  55.8 ns
sharing bed with someone 112  29.5 489  17.9 ns
no. of family members 0.040  1.08 1.004- 1.16
no. of persons in bedroom 0.038  1.13 1.01-1.26
Smoking
current smoking** 144  37.7 738  26.8 0.022  1.38 1.05-1.83
Alcohol consumption
current alcohol consumption** 292  76.8 1755  63.8 0.032  1.40 1.03-1.91
Anfavourable situation1 of life related to…
economical situation1 360 95.5 2380 87.7 ns
housing conditions1 270  71.2 1627  59.6 0.049  1.35 1.002-1.81
overal situation1 307  81.0 1980  72.6 ns
1very good or good / average, bad or very bad
Occurence of GORD-symptoms** 189  55.9 1002  42.0 ns
Medical examinations and sick leaves because of dyspeptic symptoms
Gastroscopy 44  11.6 170  6.2 ns
X-ray of ventricle 51  13.5 220  8.0 ns
being on sick leave** 11  2.9 34  1.2 0.009  3.36 1.35-8.33
H. pylori  associated diseases
gastritis 28  7.3 76  2.8 0.009  2.08 1.20-3.60
peptic ulcer disease 16  4.2 22  0.8 ns
*For binary logistic regression analyses, the variables measuring educational level were entered as
categorical variables, the crowding variables were entered as continuous variables and other variables
as dichotomical variables.  SPSS 12.0 software packages (SPSS, Inc.,Chicago, Ill.) was used.
** The question was related to the last six months.
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Table 14. Daily no. of cigarettes among smokers, and weekly amount of alcohol
consumption  in  the  last  six  months  in H. pylori-positive and -negative young adults.
Information collected by a questionnaire at the beginning of the ‘screen-and-treat’
programme.
H pylori  positive H pylori  negative
n % n % P-value*
daily no. of cigarettes 0.001
 0 - 14 89  61.0 598  74.6
 15 - 30 56  38.4 199  24.8
 > 30 1  0.7 5  0.6
weekly units of alcohol <0.0001
0 88  23.2 997  36.2
 1 - 2 115  30.3 858 31.2
 3 - 7 98        25.8 572  20.8
 8 - 20 62  16.3 252  9.2
 > 20 17  4.5 73  2.7
* Mann-Whitney’s U Test's Exact Sig. (2-sided)
Reflux-symptoms and other gastrointestinal symptoms
The  occurrence  of  GORD  symptoms  was  significantly  associated  with H. pylori
infection. Not only the frequency but also the severity of GORD-symptoms were
higher among H. pylori-positive participants (Table 15).
We could not find a significant difference between antibody-positive and antibody-
negative subjects in the severity or frequency of the other evaluated gastrointestinal
symptoms (stomach cramps, feeling of swelling in upper abdomen, regurgitation of
gastric juice, feeling of hunger, nausea, belching, diarrhoea, constipation or repeated
urgent need for defecation).
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Table 15. Occurence of GORD-symptoms in the last six months in H. pylori-positive
and H. pylori-negative young adults. Information collected by a questionnaire at the
beginning of the ‘screen-and-treat’ programme.
H pylori  positive H pylori  negative
n % n % P-value*
severity <0.0001
no harm 149  44.1 1382  58.0
mild 69  20.4 454  19.0
moderate 91  26.9 446  18.7
severe 26  7.7 92  3.9
very severe 3   0.9 10   0.4
frequency <0.0001
never or < once a month 196 53.3 1789 66.6
1-3 times / month 108  29.3 617 23.0
once a week 33 9.0 134 5.0
2-6 times / week 21  5.7 112  4.2
every day 10  2.7 34  1.3
* Mann-Whitney’s U Test's Exact Sig. (2-sided)
Medical examinations and sick leaves
Self-reported  medical  examinations  (gastroscopy  and/or  x-ray  of  ventricle)  and  sick
leaves due to upper abdominal symptoms were associated with H. pylori infection
(Table 13). There were no significant differences between H. pylori-positive and H.
pylori-negative participants in the number of doctor consultations or medications
because of upper abdominal symptoms, and in the use of ASA and NSAIDs.
H. pylori associated diseases
A history of peptic ulcer disease and gastritis were associated with H. pylori infection
(Table 13). One (0.3%) H. pylori-positive participant and two (0.1%) H. pylori-
negative participants reported history of gastric cancer (p = 0.321). Whether mother
or father had suffered from peptic ulcer disease did not reach statistical significance,
although 43 (15%) and 244 (10.5%) of the H. pylori-positive and -negative
participants, respectively, reported father’s peptic ulcer disease, and 21 (6.6%) and 93
(3.8%), respectively, that of mother’s. There were no significant differences between
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H. pylori-positive and -negative participants in the occurrence of upper abdominal
pain before the age of 16.
Situation in life and quality of life
We monitored the situation in life by a 5-graded scale (very good, good, average, bad,
and very bad) and found that a more unfavourable (average, bad or very bad) situation
in life was associated with H. pylori infection when related to economical situation,
housing conditions, and overall situation (Table 13), but not when related to general
health or health concerning stomach, daily work, family life, human relations and free
time. We evaluated the quality of life by a 5-graded scale and found no significant
differences between H. pylori-positive and -negative subjects in enjoying daily
activities, sleeping, optimism about future, ability to concentrate on daily
work/studying, decision-making, and happiness.
Independent risk factors for H. pylori infection
In multivariate analysis, the mother’s basic education, number of family members and
number of persons in bedroom in childhood household, current alcohol consumption,
current smoking, housing conditions, being on sick leave and self-reported gastritis
remained statistically significant as independent risk factors for H. pylori infection
(Table 13b).
DISCUSSION
Screening and treating for H. pylori programme (Study I)
The primary health care system in Finland provided excellent opportunities to
organize a large-scale screening and treatment programme. Three quarters of the
invited 6109 subjects participated in our studies (88% in the pilot study, 74% in 1996
and 76% in 1997-2000) and the proportion of participating females was only slightly
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higher than that of men. The participation rates were clearly superior to those of some
previous reports, although the infected subjects were required to pay most of the
expenses of the medicines used in eradication treatment themselves.  In Bristol, UK in
a double-blind placebo-controlled trial, only 39% of the invited unselected 20–59
year-old individuals participated in screening (Lane J et al., 2002). In Leeds, UK the
participation rate was even lower, at 26%, when randomly selected individuals aged
40-49 years were invited (Moayyedi et al., 2000a). In Odense, Denmark, the
participation rate was 63% in a study where 20,000 individuals aged 40 to 65 years
and representing general population were randomized to screening and eradication for
H. pylori or to a control group (Wildner-Christiansen et al., 2003). The studies in
Bristol, Leeds and Odense assessed the effect of H. pylori screening in the
community. However, the studies in Leeds and Bristol mainly concentrated on the
question whether to treat or not to treat H. pylori-positive individuals in general,
whereas the Danish study, like our own study, focussed on the question whether to
screen or not to screen on a population level (Hansen et al., 2008).
Of note is the high acceptance of antimicrobial therapy for the eradication of H. pylori
infection. The eradication rates for first-line therapy were 89.8% in the pilot study,
and 82.2% and 77.6% per-protocol and 71.9% and 62.9% in an intention-to-treat
analysis in subjects invited in 1996 and 1997-2000, respectively. Resistance to
metronidazole was later demonstrated to be common among Finnish H. pylori isolates
(Koivisto et al., 2004) and thus, antimicrobial resistance was probably the major cause
for treatment failures. A longer duration of therapy or higher PPI doses could possibly
have increased the eradication rates, when taking into account host related PPI
metabolism and a high bacterial burden with H. pylori (Graham and Shiotani, 2008).
However, the triple-therapy used in our study was in line with the first Finnish
guidelines for the management of H. pylori infection in 1996 (Färkkilä et al., 1996).
On the basis of this active intervention, the initial H. pylori seroprevalence rates were
calculated  to  have  decreased  from 39% to  19% in  the  pilot  study,  from 12% to  4%
among subjects aged 15 to 40, and in the extension of the study, from 3% and 27%
among the 15 and 45-year-old subjects to 2% and 12%, respectively.
We started the voluntary ‘screen-and-treat’ programme before the first European
guidelines for the management of H. pylori infection (EHPSG, 1997) were published.
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According to these guidelines, it was recommended to screen and treat young
dyspeptic patients without alarming symptoms by primary care physicians for H.
pylori infection using UBT or locally validated serology in screening, but screening of
asymptomatic individuals was not recommended. According to the latest update of the
European guidelines, the Maastricht III Consensus Report, H. pylori ‘test-and-treat’ is
appropriate for patients with uninvestigated dyspepsia (Malfertheiner et al., 2007). In
high prevalence populations this is the strategy of choice in adult patients suffering
from functional dyspepsia, while in areas of low H. pylori prevalence (<20%) the
strategy is less effective and empirical acid suppression treatment with PPIs is
recommended as an equivalent option (Malfertheiner et al., 2007).  In our study,
where also asymptomatic individuals were included, the prevalence of H. pylori-
infection increased by age-group.  In the pilot study, most of the participants
represented a high prevalence population, while most of the participants in the
‘screen-and-treat’ programme from 1996 on represented a low prevalence population,
since the seroprevalence rate was less than 20% among 15-35 year-old subjects in
both of the study-phases.
The prevalence of dyspepsia is about 15 to 50% (Kay and Jørgensen, 1994; Agréus et
al., 1994; Ford et al., 2007), and between 33 and 56% of the patients suffering from
dyspepsia are infected with H. pylori (Bernersen et al., 1992; Agréus et al., 1995;
McColl et al., 1997). It has been calculated, that about 10 % of the patients suffering
from functional dyspepsia could benefit from successful H. pylori eradication
treatment (Moayyedi et al., 2005), and that 30 individuals with H. pylori would have
to  be  treated  to  prevent  one  person  consulting  their  doctor  for  dyspepsia  after  two
year’s follow-up (Lane et al., 2006). It seems probable that a much longer follow-up
period after eradication treatment is needed to show a more significant reduction in
total dyspepsia-related health care costs (Ford et al., 2005). Although the prevalence
of H. pylori infection was low at the base-line and the fact that there were also
asymptomatic persons in our study, individuals successfully treated obviously
benefitted from the treatment, and moreover, also the risk of possible complications of
the infection like peptic ulcer disease, atrophic gastritis and gastric cancer is reduced.
It will be seen in future, how much this intervention has affected the incidence and
health-costs of these complications. On the other hand, possible side-effects with
eradication therapy and anxiety due to awareness of H. pylori infection may have
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troubled the participants, although sever adverse effects with eradication therapy have
been seldom reported (Lee et al., 2006).
Indications for H. pylori eradication have widened. According to the latest European
guidelines (Malfertheiner et al., 2007), the recommended indications for H. pylori
eradication are: peptic ulcer disease, MALT lymphoma, atrophic gastritis, gastric
cancer resection, gastric cancer in a close relative, long term maintenance treatment
with PPIs, functional dyspepsia, unexplained iron deficiency anaemia, idiopathic
thrombocytopenic purpura, and the start of long term maintenance treatment with
NSAIDs.  It  is  well-known  that  about  95%  of  the  duodenal  ulcers  are  caused  by H.
pylori infection, and successful H. pylori eradication prevents the recurrence of the
ulcer disease (Ford et al., 2004). Of gastric ulcers commonly associated with the use
of NSAIDs, about 70% are caused by H. pylori (Ford et al., 2004). In Finland, the
prevalence of H. pylori associated peptic ulcer disease has declined (Veijola et al.,
2005a; Koivisto et al., 2005), due to declining prevalence rate of H. pylori infection
and to active antimicrobial treatment for the infection. In our study, peptic ulcer
disease was detected in 12.1% of the infected patients and in 1.2% H. pylori-negative
patients (p<0.0001) (Study II). In rarely occurring MALT lymphoma, 62% of the
patients  with  a  low  grade  gastric  MALT  lymphoma  demonstrated  a  complete
remission after successful eradication (Malfertheiner et al., 2007). In about one half of
those infected with H. pylori, gastritis proceeds to atrophic gastritis resulting in a loss
of mucosal glands and decreased helicobacter colonization, and to intestinal
metaplacia, which are regarded as precursors for gastric cancer  (Kuipers et al., 1995;
Valle et al., 1996; Lauwers, 2003). The development of atrophic gastritis can be
stopped by H. pylori eradication, and atrophic changes on gastric mucosa can turn to
normal after successful eradication (Kokkola et al., 2002).
H. pylori infection has been classified as a first class carcinogen for gastric cancer
(International Agency for Research on Cancer, 1994). It is estimated that 60-90% of
gastric cancers are associated with H. pylori (Malfertheiner et al., 2005). In Finland,
the decline in the local prevalences of H. pylori infection appeared to predict the
declining local incidences of gastric cancer after a median latency of 20 years
(Rehnberg-Laiho et al., 2001). In reports on the effect of H. pylori eradication on the
development of gastric cancer, the development of cancer was prevented only in
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patients without atrophic gastritis and intestinal metaplasia before eradication therapy
(Wong et al., 2004). Although it has been suggested that H. pylori eradication for
gastric cancer prevention should be evaluated in populations at risk (Malfertheiner et
al., 2007), screening and treating the general population for H. pylori has not yet been
recommended. By adopting the ‘screen-and-treat’ programme for young adults, as
presented here, it may be possible to cure the infection before the development of pre-
neoplastic conditions and also the transmission of the infection from parents to
children may be prevented.
An epidemiological questionnaire was returned by 99.7% of the participants in 1996.
Our results on the risk factors of H. pylori infection were in agreement with reports
from elsewhere (Malaty and Graham, 1994; Everhart et al., 2000; Koch et al., 2005;
Bures et al., 2006) and the results from the multivariate analysis confirmed that a low
education of the mother and crowded living conditions in the childhood household
were also in Finland associated with H. pylori infection. In addition, multivariate
analysis showed that current smoking, current alcohol consumption, housing
conditions, and being on sick leave due to dyspeptic symptoms remained statistically
significant as independent risk factors for H. pylori infection in our study. H.pylori
infection seemed to be a good indicator for an individual’s socioeconomic situation,
as the economical situation, housing conditions and the overall situation of life were
found in univariate analyses to be significantly more favourable in H. pylori negative
subjects. Although most of the significant risk factors in univariate analysis were
independently associated with H. pylori infection in multivariate analysis, many of
them could possibly reflect a lower socioeconomic status in childhood household.
Special role of serology (Studies I-IV)
Our research group has used serology for many years and it has proved to be a highly
accurate method both in diagnosing H. pylori infection (Kosunen et al., 1992,
Oksanen et al., 1998) and in confirming the treatment success (Kosunen et al., 1992,
Veijola et al., 2005a). On the basis of our extensive experience in serology this
method was also chosen for screening in the present study. Recommendations for the
diagnostic methods used for detecting H. pylori infection have changed and now it is
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generally accepted that the role of serology in detecting the infection is crucial. The
latest European guidelines on the management of H. pylori infection, the Maastricht
III Consensus Report underlined the special role of serology compared to other
diagnostic tests (Malfertheiner et al., 2007), since PPI treatment prior testing can lead
to false negative results in other diagnostic tests than serologic assays. Serological
tests are recommended to asses H. pylori infection also in patients suffering from
bleeding ulcers and in conditions with a low bacterial density (gastric atrophy, MALT
lymphoma);  both  invasive  and  other  non-invasive  tests  have  demonstrated  a  limited
sensitivity in those patients. However, office-based serological tests or near patient
tests are not recommended due to their low accuracy (Malfertheiner et al., 2007).
Although the best quantitative serological tests show high sensitivity and specificity,
all tests are not equal in accuracy and it is recommended to validate antibody assays
locally (Feldman et al., 1995; Herbrink and van Doorn, 2000). The accuracy of a
diagnostic  test  is  strongly  dependent  on  the  prevalence  of H. pylori infection
(Leodolter at al., 2001; Oksanen et al., 2001). In areas of low H. pylori prevalence, the
diagnostic test used may demonstrate a lower positive predictive value resulting in an
increased number of false positive test-results. We evaluated the EIAs used in our
studies  (I,  II,  III,  IV)  in  different  age-groups  (Study  II).  Both  the  in-house  and
commercial EIAs demonstrated high specificity in subjects below 50 years of age,
with a low prevalence rate of H. pylori infection. However, serologic tests may have a
lower accuracy if the population has been actively treated for H. pylori infection; after
successful H. pylori eradication therapy, the antibodies decline slowly to the normal
level staying elevated even for ten years in some of the successfully treated patients
(Veijola et al., 2007). In our study (Study I), in the case of earlier treated participants,
UBT  was  used  to  verify  the  serologic  results  to  confirm  the  diagnosis  of H. pylori
infection.
Follow-up after treatment is recommended and the latest European guidelines
(Malfertheiner et al., 2007) advise to confirm the eradication treatment for at least
four weeks after treatment using UBT. If UBT is not available, according to the
recommendation, a laboratory-based stool test using monoclonal antibodies could be
used in assessing the success of treatment. Locally validated serologic assays with a
high specificity and sensitivity as used in our study (Study I) provide a reliable, easy
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and cheap method, not only to diagnose H.pylori infection (Kosunen et al., 1992;
Herbrink and van Doorn, 2000), but also to confirm the success of treatment
(Kosunen et al., 1992; Rautelin and Kosunen, 2004). Using serology as a follow-up
method after treatment requires taking a pre-treatment serum, a post-treatment serum
four to six months after eradication therapy and testing the samples in parallel in the
same  assay  to  determine  the  decline  of  antibody  titres.  In  our  study  (Study  I),  we
confirmed in the population-based ‘screen-and-treat‘ study the treatment failures by
using UBT in most cases at least before the possible second course of treatment and
found only one individual with a discrepancy between serology and UBT.
Age-dependent accuracy of H. pylori antibody assays, with special reference to
atrophic gastritis (Study II)
Patients with atrophic corpus gastritis often have positive H. pylori serology, although
microscopical examination (Karnes et al., 1991; Testoni et al., 1996), culture of
biopsy samples, and even the UBT remain H. pylori negative (Kokkola et al., 2000).
These particular patients may still be infected as demonstrated by rapidly falling
antibody titres after therapy (Kokkola et al., 1998).  We evaluated (Study II) the
accuracy of the EIAs used in our studies (I-IV) regarding to the presence of atrophic
gastritis. Atrophic gastritis was detected in 37% of the infected patients and in 14%
of the H. pylori-negative patients and it was more common in older age-groups
appearing in 10%, 17% and 40% of the patients aged 15 to 49, 50 to 64, and >64
years, respectively. The sensitivities of the both IgG tests were high in all age-groups,
but the specificities for in-house and Pyloriset IgG tests declined by age. However,
the lower specificities for the older age-groups might be due to false negative results
of the reference tests (histology and culture), in which mucosal atrophy with a
diminished bacterial density can lead to false negative test results (Malfertheiner et
al., 2007). The exclusion of ‘false’ positive results for patients with atrophic gastritis
improved the specificities for both of the tests in older age-groups. In our study, H.
pylori positivity was defined as a positive result in histology or culture. These
invasive methods seemed to show a lower sensitivity in detecting H. pylori infection
in patients with atrophic gastritis, supporting the special role of serology in
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diagnosing H. pylori infection in patients with atrophic gastritis, according to the
latest European Guidelines (Malfertheiner et al., 2007).
Changes in IgA and CagA levels (Studies III and IV)
H. pylori infection induces an immunologic response with circulating antibodies
which is not able to eradicate the bacterium from the gastric mucosa. Most infected
subjects have specific circulating IgG antibodies, but systemic IgA antibodies for H.
pylori are elevated in approximately two-thirds of the infected subjects (Kosunen et
al., 1992), and  2-7% of the infected individuals show an elevated IgA level alone
(Kosunen et al., 1992; Kosunen et al., 1997; Jaskowski et al., 1997). The prevalence
rates of H. pylori antibodies increase by age (Kosunen et al., 1989; Andersen et al.,
1996), due to the so called cohort phenomenom of H. pylori infection (Banatvala et
al., 1993a; Kosunen et al., 1997). The sensitivity of H.  pylori IgA asssays is reported
to be lower than that for IgG, especially in younger age-groups (Kolho et al., 2002).
Also in our studies, the seroprevalence rate of H. pylori infection, as measured by H.
pylori IgG and IgA antibody results combined, increased by age (Study I) in 1994
from 5 % to 69% in 15 to 75-year-old subjects, and  in 1996 from 4 % to 22% in 15 to
40-year-old individuals in the 5-year age groups.  The sensitivities of the both IgA
tests were low among those aged 15 to 49 years, but clearly increased by age, for the
commercial EIA from 52% among those aged 15 to 49 to 86% among those aged 65
or more.
Serological tests, especially those detecting antibodies against the specific
immunogenic antigen CagA, are regarded as the best method to document the link of
H. pylori infection with gastric cancer (Cover et al., 1995; Malferheiner et al., 2007).
H. pylori strains  are  either  CagA-positive  or  CagA-negative  based  on  whether  they
posses the CagA protein encoded by the cagA gene. CagA is present in 40 to 70% of
H. pylori strains, and it is associated with peptic ulcers, precancerous conditions and
gastric cancer in the West according to several studies (Cover at al., 1995; Kuipers et
al., 1995; Parsonnet at al., 1997; Kusters et al., 2006).  Furthermore, an IgA antibody
response during H. pylori infection has also been associated with peptic ulcer disease
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and gastric cancer (Aromaa et al., 1996; Kosunen et al., 2005), and production of IgA
antibodies has been associated with a CagA-positive infection (Rautelin et al., 2000).
We studied the changes in the prevalence rates and levels of H. pylori IgA antibodies
(Study III) and CagA antibodies (Study IV) in two decades’ follow-up by utilizing
frozen  serum  samples.  The  use  of  frozen  sera  was  based  on  the  fact  that H. pylori
antibodies tolerate multiple freezings and thawings (Pearce et al., 1996, Blaser et al.,
1991).
We showed (Study III) that the increase in the prevalence rate of H. pylori IgA
antibodies according to age (Kosunen et al., 1989; Andersen et al., 1996) was due not
only to the birth cohort phenomenon and seroconverters but also to rising IgA titres
during chronic infection. In several subjects, the initial normal IgA antibody levels
later  rose  above  the  cut  off  level,  increasing  the  proportion  of  IgA  seropositive
subjects in older cohorts.  The maturation of the IgA response in H. pylori infection
appeared to continue into adulthood. Interestingly, IgA production, seen both in a
greater number of responders and as higher IgA titres has been found to be stronger in
children infected with a CagA-positive strain than in children with CagA-negative
strains (Kolho et al., 1999).
The seroprevalence rate of CagA antibodies (IV) declined significantly during the two
decades preceding follow-up, which paralleled the overall decline in H. pylori
seroprevalence in Vammala during that time (Kosunen et al., 1997). Furthermore, the
decline in seroprevalence of  CagA-positive H. pylori strains in subjects aged 14 to 44
years was significantly greater than that for H. pylori CagA-negative strains. This
might  be  associated  with  the  repeated  antibiotic  usage  over  the  course  of  childhood
(Blaser, 1999) and the evidence that CagA-positive strains were more susceptible than
CagA-negative strains to eradication treatment (van Doorn et al., 1997). It remains to
be seen in the coming years whether the more rapid decline of H. pylori CagA-
positive strains will affect the prevalence rate and clinical importance of IgA
antibodies, as well as the outcome of severe complications of H. pylori infection.
Changes in overall H. pylori-positivity and CagA antibody status were also studied by
utilizing the paired sera from 221 subjects obtained both in 1973 and 1994 (Study IV).
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In total, only 5.4% of subjects had a change in overall H. pylori status during the two
decades follow-up period giving a crude seroconversion rate of 0.4% and a crude
seroreversion rate of 0.13% per year. In addition, nearly identical serum antibody
levels to CagA and to the acid glycine extracted antigen (in-house IgG and IgA) in the
same individuals 21 years apart were found, which confirms the stability of antibody
responses and the longstanding equilibrium between hosts and their H. pylori
populations (Blaser and Kirschner, 1999).
The long-term changes in the levels of H. pylori IgA antibodies were measured both
in Study III and Study IV utilizing in part the same frozen serum samples. However,
the study designs of these two studies were different in three aspects; 1) H. pylori
positivity was defined in different way. In Study III, the persisting H. pylori infection
was defined as a positive IgG antibody result at the beginning and at the end of the
follow-up period. When evaluating the changes in antibody levels and antibody status,
the positivity was based on antibody level exceeding the cut-off value for the test
evaluated. In study IV, H. pylori positivity was defined as a positive result in any of
the three serological assays used (in-house IgG, in-house IgA and CagA). H. pylori-
negative status was defined when all three assays were negative.  2) The changes in
the antibody levels were calculated as median titres/values in Study III and as mean
titres in Study IV. 3) When evaluating long-term changes in titres, the criteria for
included  subjects  were  different.  In  Study  III,  only  those  subjects  with  a  persisting
positive IgG and IgA response were included, while in Study IV, all subjects who
were IgG-seropositive in the beginning of the follow-up were included.
Public health perspective (Study I)
H. pylori infection is related to gastric cancer, associated with high morbidity and
poor prognosis, and peptic ulcer disease, which demonstrates high morbidity and
modest mortality. The information on H. pylori infection has not been effective at
primary  care  level,  according  to  some  reports;   In  a  worldwide  survey,  of  the  GPs,
81%, 85% and 61% knew the causal relationship of H. pylori with gastric and
duodenal ulcers and gastric cancer, respectively (Huang et al., 2003). In a study from
England, only 10% of those patients who had peptic ulcer disease had been prescribed
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eradication therapy (Wright et al., 2001). There are large numbers of people who have
suffered from a documented peptic ulcer but who have not been treated for H. pylori.
In  young  people  the  prevalence  of H. pylori is  low  and  still  declining  and  the
prevalence of peptic ulcer disease is low. Since ulcer disease has a high prevalence in
older people, it has been suggested, that if we aim to eliminate ulcer disease, we have
to focus on the prevalent cases (Lai et al., 1999, de Boer 2000) or target the
population who regularly uses acid suppressants (deBoer 2000).
H. pylori eradication seems to be the most practical means of preventing gastric
cancer and peptic ulcer disease, but population screening among asymptomatic
individuals is suggested only for populations with a high risk for gastric cancer and
among those individuals also listed in the latest European guidelines appropriate for
eradication  therapy  (Forman  and  Graham,  2004,  Malfeltheiner  et  al,  2007).   One
approach for screening and treatment for H. pylori infection in populations at risk
could be to focus on migrant populations in the West, among which the prevalence of
the infection is high (de Vries et al., 2008).
Intervening in otherwise healthy individuals requires critical analysis to weigh up the
possible harms of a ‘screen-and-treat’ intervention. From a public health perspective,
induction of antimicrobial resistance due to antibiotic combinations used in
eradication is expected to be of less importance than that of antibiotic prescription for
other reasons, since metronidazole, amoxicillin and clarithromycin as sole treatments
are more commonly prescribed for other indications in a society. According to the
hypothesis that H. pylori could be one of the microbes counteracting atopy, an
increase in IgE-based allergy may occur in a population actively treated for H. pylori
infection (Kosunen et al., 2002).
Although the prevalence rate of H. pylori infection has decreased in Finland (Kosunen
et al, 1997), and the prevalence of H. pylori associated peptic ulcer disease has
declined in Finland (Veijola et al., 2005a; Koivisto et al., 2005),  the severe
consequences of the infection still exist. Indications for eradication treatment have
widened and also public awareness of the infection and associated complications has
increased the need for testing and treating it. In Finland in ordinary clinical practise,
all patients found to be infected with H. pylori can receive an eradication treatment
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when requested. From a public health perspective H. pylori screening and treating has
the potential to reduce the burden of peptic ulcer disease and possibly that of
dyspepsia in the community and will presumably prevent gastric cancer, if the target
population is young adults as in our study. Although the prevalence of H. pylori
infection was low even before the intervention, it remains to be seen in the coming
years, how much this intervention will affect the prevalence and related health costs
of H. pylori associated diseases.
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CONCLUSIONS
1. The decline of H. pylori gastritis was accelerated by the programme. The primary health
care system of Finland provided an excellent opportunity to organize this large-scale
‘screen-and-treat’ programme. In the pilot study, the initial seroprevalence rate of 39%
was calculated to have declined to 19% after the intervention. In the ‘screen-and-treat’
programme, the initial seroprevalence rate of 12% among subjects aged 15 to 40 years in
1996 was calculated to have decreased to 4%, and the initial seroprevalence rates of 3%
and 27% among subjects aged 15 and 45, respectively, in 1997-2000 were calculated to
have decreased to 2% and 12% after the programme.
2. Crowding variables in the childhood household, low education of the mother, smoking
habits and alcohol consumption, unfavourable housing conditions, and sick leave due to
dyspepsia were statistically significant independent risk factors for H. pylori infection in
this young Finnish adult population.
3. The IgG antibody test was highly accurate in subjects aged 15 to 49, but the specificity
declined in older age-groups, in which the prevalence of atrophic gastritis increased. The
sensitivity of the IgA test increased and the specificity decreased by age. The exclusion
of ‘false’ positive results for patients with atrophic gastritis clearly improved the
specificities of both the tests for older age-groups.
4. The increase in the number of IgA-antibody-positive H. pylori patients with age was due
not only to the birth cohort phenomenon and seroconverters but also to rising IgA titres
during chronic infection. In several initially IgG-antibody-positive subjects, the initial
normal IgA antibody levels later rose above the cut off-level, increasing the proportion of
IgA seropositive subjects in older cohorts.  The elevated IgA antibody levels significantly
rose during infection.
5. The proportion of subjects infected with CagA+ H. pylori strains as measured by CagA
antibodies had declined more rapidly than the proportion of subjects infected with CagA-
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